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Interferon-gamma/Hypoxia Primed Mesenchymal Stem Cells for an Improved 
Immunosuppressive Cell Therapy 
Holly Wobma 
 
Mesenchymal stem cells (MSCs) are promising candidates for treating diverse inflammatory 
disorders due to their capacity to be immunosuppressive. This phenotype is not present at 
baseline but develops in response to instructive cues. To date, clinical trials use cells grown in 
basic culture conditions, anticipating the cells will acquire a useful phenotype in response to in 
vivo cues. This strategy has failed to produce any FDA approved therapies, based on inconsistent 
efficacy. This thesis explores whether priming MSCs prior to administration can lead to a more 
uniformly therapeutic phenotype, and it details the design of an optimal in vitro priming regimen. 
Because interferon gamma (IFN-γ) is known to induce an anti-inflammatory state in MSCs, 
hypoxia can confer survival benefits, and both cues coexist in known situations of immune 
tolerance, we hypothesized dual IFN-γ/hypoxia priming would yield a superior 
immunosuppressive MSC therapy. We show that priming MSCs with hypoxia or IFN-γ alone 
improves their ability to inhibit T-cells in vitro, but combining these cues results in additive 
improvements. We next characterize the proteomic and metabolomic changes MSCs undergo 
when exposed to single or dual IFN-γ/hypoxia priming. While IFN-γ induces MSCs to suppress 
inflammation and fibrosis, hypoxia leads to cell adaptations to low oxygen, including 
upregulation of proteins involved in anaerobic metabolism, autophagy, angiogenesis, and cell 
migration. Dual priming results in additive effects, with many instances of synergy. Finally, we 
show initial evidence that dual primed MSCs are better able to inhibit disease progression in a 
mouse model of acute graft-vs-host disease (GvHD).  
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1.1 Mesenchymal Stem Cells (MSCs) 
Mesenchymal stem cells are multipotent progenitor cells that can be isolated from a wide range 
of tissues, most commonly from bone marrow, adipose tissue, or umbilical cords,1,2 although 
they can also be differentiated from embryonic and induced pluripotent stem cells.3,4 While there 
is some debate surrounding how to best define them, demonstration of tri-lineage differentiation 
capacity into osteocytes, adipocytes, and chondrocytes is thought to be a minimal criterion.1 
They should additionally have surface expression of CD73, CD90, and CD105 and lack 
expression of hematopoietic markers (CD11b, CD14, CD19, CD34, CD45 and HLA-DR).1 
 Because they are easy to isolate, do not raise the same ethical concerns as embryonic 
stem cells, do not form tumors (teratomas), and can be differentiated into a wide variety of cell 
types (Figure 1),5 MSCs have traditionally been explored as a source cell to be differentiated 
into mature cell types for tissue engineering and regenerative medicine applications.  
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Figure 1 Demonstration of the diverse differentiation potential of MSCs (DiMarino et al.5) 
 
In the field of tissue engineering, many groups have used MSCs for engineering bone, 
cartilage, and other connective tissues.6,7 Others have tried to use differentiated MSCs as mature 
cell therapies, creating neurons for central and peripheral nervous system damage,8–10 
cardiomyocytes for treating heart damage,11 and so forth.  
 Despite their multipotent differentiation potential, it is not clear that endogenous MSCs 
naturally differentiate to aid in tissue repair in vivo. Indeed, there is a growing appreciation that 
their normal physiological role may have more to do with their paracrine effects,2,12 based on in 
vivo observations that MSC delivery without differentiation and engraftment into injured tissues 
still leads to regeneration via alternative therapeutic mechanisms.13–15 MSCs have been shown to 
release numerous growth factors (GFs) (e.g., EGF, FGF) and angiogenic factors (e.g., VEGF, 
DiMarino et al. Mesenchymal stem cells in tissue repair
FIGURE 2 |The mesengenic process. Mesenchymal stem cells are multipotent and possess the ability to proliferate and commit to different cell types based
on the environmental conditions. They also may be redirected from one lineage to another.
and ascorbic acid. After 21 days, the cells can be stained with
van Kossa’s stain to reveal osteogenic differentiation or chemically
analyzed for calcium accumulation (25–27).
FUNCTIONAL EFFICACY
A variety of functional assays can also be used to measure MSC
efficacy. The point of these assays is to measure the ability of the
MSCs to induce a specific effect.MSCs have been shown to have an
immunosuppressive effect on T-cells (15) both as an activity and
also in their ability to produce lymphokines (28). Traditional T-cell
proliferation assays using the incorporation of tritiated thymidine
3 days post stimulation in the presence of antigen presenting cells
with and without MSCs can be an easy 3-day assay for MSC effi-
cacy. These studies can be further simplified by using one of the
newer assays that involve using T-cell ATP levels as an indicator
of activity (29). In these studies, no radiolabel is required and
the assay is a direct 18-h output. T-cell cytotoxic cells can also
be used as indicators of MSC efficacy for the same purpose as
the T-cell activity assay (30, 31). The nteresting issue is the dif-
ferences between the assays in terms of MSCs effector function:
the MSC preparation which s ppresses the T-cell proliferative
responsesmaynot be as effective at attenuating the ability of T-cells
to mediate a cytotoxic response.
IN VIVO VERSUS IN VITRO MODELS
Several in vivo experimental studies have shown the value of allo-
geneic or xenogenic MSCs for a variety of disorders including:
sepsis, hepatic failure, acute renal failure, and myocardial infarc-
tion (32). The issue with in vivo models of efficacy has to do with
the validity of the model itself and the inherent variability that
exists with in vivo experimentation. Th other issue that needs to
be addressed is the assessment of efficacy and theduration required
to obtain that outcomes. I vivo models are ore expensive and
are inherently more time consuming with the issue of translation
to human applicatio s a major focus. The choice of model, dura-
tion of MSC exposure, dosing required to induce the effect, and
final outcome can be interpreted as strong indicators of the abil-
ity to use MSCs in vivo. Interestingly there have been a variety of
studies in which xenographic hMSCs have been utilized in animal
models that show similar effectiveness to allogenic and autolo-
gous MSCs (6, 12). In acute renal failure in mice, intravenous
MSC therapy hastened renal tubular epithelial cell recovery (4),
and markedly improved mortality from peritoneal sepsis in mice
regardless of whether the MSCs were allogeneic or autologous
(33). For example, the documented studies involving lung inflam-
mation, administration of MSCs was post-injury suggesting the
injury requirement in the function (recruitment or activation)
of the MSCs to the interface of lung injury. These studies would
provide in vivo models of efficacy and would define the potential
for different “efficacy” and “potency” directives depending on the
injury itself. A few examples of specific models will be discussed.
LUPUS
Mesenchymal stem cells have been shown to have a profound
impact on the impact of disease progression in the murine model
of lupus (34). Murine lupus can be induced in 6- to 7-week-
old female C57BL6 mice by immunization with an emulsion
Frontiers in Immunology | Inflammation September 2013 | Volume 4 | Article 201 | 4
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PDGF), and express immunomodulatory proteins and lipids capable of subduing both the innate 
and adaptive immune response (e.g., IDO, PGE2, HGF).16 Because of these paracrine effects, 
MSCs could potentially be used to treat a wide variety of conditions, including acute 
inflammation, autoimmune disease, and graft rejection. 
 
1.2 MSCs as Immunomodulatory Cells 
1.21 Immune privileged or not? 
Around 1998, researchers at Osiris Therapeutics started to present evidence that allogeneic 
MSCs could inhibit T-cells in gold standard immune activation assays and that MSCs were 
Figure 2 Historical perspective on the universal donor hypothesis for allogeneic MSCs (Ankrum  et al.16) 
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“immune priviledged”.16 They subsequently proposed the notion of universal, allogeneic MSC 
therapies, a striking contrast to the related field of hematopoietic stem cell transplantation, where 
human-leukocyte antigen (HLA) matching between donor and recipient is paramount.  
 Over the next 5 years, the scientific community latched onto the notion of MSCs being 
immune privileged, even capable of showing an immunosuppressive effect in xenogeneic models 
without any negative sequelae related to rejection.17,18 More recent evidence, however, supports 
that allo- and xeno-MSCs do express immunogenic proteins, but the influence of these is 
partially offset by the expression of a variety of immunosuppressive and immune protective 
factors (Figure 2).16 Notably, even if a slight allogeneicity increases the clearance rate of allo or 
xeno-MSCs, they still have a lasting impact on the immune system. This has been described as 
the “hit-and-run” effect,19,20 and it is one reason why clinicians are optimistic that even single 
doses of MSCs could provide a long-term benefit to patients. 
 
1.2.2 Mechanisms of immunomodulation 
Early studies provided evidence that MSCs act through paracrine mechanisms such as through 
the secretion of exosomes and immunosuppressive proteins. While true, several surface (e.g. PD-
L121) and intracellular (e.g. IDO22) factors have been identified as being critical to the 
therapeutic function of MSCs, and there is also evidence that they may mediate their effect 
through the formation of apoptotic bodies.23 While the relative importance of these diverse 
mechanisms is hard to quantify, it is at least clear that the repertoire by which MSCs act as 
immunomodulatory cells is highly diverse. We summarize factors that have been associated with 
MSC immunosuppression in Table 1.  
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Table 1 The numerous immunomodulatory factors implicated in the ability of MSCs to be immunosuppressive and 
immune protected. * Mϕ – macrophage; APC – antigen presenting cell; DC – dendritic cell; T-reg – regulatory T-
cell; NK cell – Natural Killer Cell 
 
1.2.3 Homing of cells 
Beyond the ability to directly modulate immune cell activity, MSCs have also been shown to 
mimic leukocytes in their ability to home to inflamed sites. Detailed studies of MSC homing 
Factor Immunomodulatory Effects Target  
IDO22,23 • Limits T and NK cell proliferation 
• Induction of tolerogenic DCs & Tregs 
• Promotes Th1à Th2 switch 
• Promotes M2 Mϕ polarization 




HLA-G24 • Inhibition of T & B cell proliferation 
• Inhibition of cytolysis by CD8+ & NK cells 
• Induction of T-regs 
ILT2 
ILT4 
KIR2DL4 CD160  
HLA-E25 • Can activate (NKG2C) or inhibit (NKG2A) NK cell mediated lysis; 
higher affinity for inhibitory receptor 
• Blocks lysis by CD8+ T cells 
CD94/NKG2A 
CD94/NKG2C 
TGF-β26 • Induction of T-regs TGFBR1 
HGF27 • Decreases cytotoxic activities of NK & CD8+ T cells 
• Increases neutrophil migration & activity 
• Reduces antigen presentation by APCs 
• Promotes pro-tolerogenic DCs & T-regs  
• Promotes tissue repair by macrophages 
• B cell differentiation (once activated) 
c-Met 
LIF28 • Inhibits lymphocyte proliferation 
• Contributes to T-reg formation 
LIF-R 
PGE226 • Suppression of T cell activation & proliferation 
• Can alter Mϕ phenotype 
• Inhibits Th17 differentiation 
EP2  
EP4  
NO26 • Acts short distance to inhibit T cell proliferation & induce T cell 
apoptosis 
• May be more important in mice than humans 
Many via forming 
reactive nitrogen 
species 
TSG-615 • Participates in extracellular matrix remodelling 
• Anti-inflammatory/limits pro-inflammatory response 
• Modulates leukocyte migration 
CD44 
CD5929 • Blocks formation of membrane attack complex, protecting cell from 
complement mediated destruction 
C9  
 
PD-L121 • Co-inhibitory signal in activated T-cells 
• Promotes T-cell anergy & apoptosis 
PD-1  
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suggest that there are both active and passive mechanisms at play.30 Inflamed tissues exhibit 
vasodilation such that blood flow is shunted towards the damaged site. Leukocytes exit 
circulation via the expression of surface adhesion molecules on activated endothelium (and 
leukocytes),31 and MSCs may leave circulation in a similar manner (active). However, they may 
also migrate due to more physical forces (passive). MSCs are large cells, with a diameter that can 
be larger than the lumen of microvasculature. Thus, as they attempt to flow through, their course 
will be naturally slowed, and they may transmigrate through the endothelium rather than 
continue through the lumen of the blood vessel.32 This could be facilitated by the leaky 
vasculature common to inflamed tissues and the remodeling of the local extracellular matrix 
(ECM). There is some speculation that chemokines could also contribute to MSC homing. For 
example, the SDF-1/CXCR4 axis could contribute to migration towards the bone marrow. 
However, MSCs do not seem to uniformly express this chemokine receptor, and thus 
investigators that have wanted to augment cell migration have done so by genetically 
engineering the cells to overexpress the desired chemokine receptor.33–36  
 
1.2.4 Summary of potential as an immunomodulatory cell therapy 
Given that MSCs home to the diseased site, exhibit a diverse repertoire of immunomodulatory 
factors, and can be used allogeneically, they appear to be ideal candidates for treating conditions 
where there is an overactive immune response. Intuitive examples of such disorders include 
organ rejection, sepsis, and autoimmune disease. However, pathological inflammation plays a 
role in many other disease processes, including conditions as disparate as depression and 
atherosclerosis.37,38 While our understanding of how to use MSCs in patients is still in its 
infancy, clinical trials are starting to provide some insights.  
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1.3 Human Clinical Trials and their Challenges 
1.3.1. Clinical trials show inconsistent and unclear efficacy 
Over the past decade, there have been over 800 registered clinical trials (clinicaltrials.gov) using 
MSCs to treat a wide variety of pathologies.23 While trials have clearly demonstrated a strong 
safety record,39 the efficacy of MSCs has been modest and inconsistent.40,41 For example, one of 
the most extensively explored applications has been for treatment of heart disease.  
Initial preclinical studies in large animal models (porcine, canine, ovine) showed 
promising data for treatment of acute myocardial infarction (MI),42,43 subacute MI,44,45 and 
chronic ischemia,46 using standard benchmarks of cardiac health such as ejection fraction, left 
ventricular end-diastolic volume, contractility, scarring, and vascular density.  
Similar studies were then conducted in human patients such as the phase I/II POSEIDON 
trial, which showed improved ejection fraction, fewer arrhythmic events, and reduced cardiac 
hypertrophy in patients after acute MI.47 Results for chronic ischemia followed the same trends, 
as the PROMETHEUS and TAC-HFT trials all showed significant decrease in scar size after 
injection of MSCs, leading to better perfusion and contractility.48,49 Based on these and other 
promising phase I/II data, phase III trials followed. However, these results were less 
encouraging. For example, the BOOST trial showed that intracoronary delivery of MSCs 
improved left ventricle ejection but this difference was no longer significant after 18 months.50 
This questionable efficacy was not unique to cardiac studies. Two phase III trials of Prochymal, 
a commercial MSC therapy developed by Osiris Therapeutics, did not meet their primary end 
point for treatment of graft-vs-host-disease, and in other indications, Osiris’s testing did not fare 
much better. A phase III trial geared toward Crohn’s disease was discontinued, while treatment 
of chronic obstructive pulmonary disease also failed to meet its efficacy end point.51,52 To this 
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day, there are still no FDA approved MSC therapies, although many companies and academic 
clinicians are actively pursuing clinical trials. 
 
1.3.2 Cited reasons for poor clinical trial outcomes  
Many explanations have been offered for why MSCs continue to fail in clinical trials despite 
encouraging animal model data.21,22,53 For example, contrary to animal studies which use fresh, 
low-passage MSCs, most clinical trials have used industrially manufactured, frozen MSCs. 
Given the higher quantities of cells needed in human (vs. mouse) studies, the cells may be over-
expanded, and MSC immunomodulatory capacity is known to decline with increasing passage 
number (cell senescence).23,52 Most manufactured products are also cryopreserved and thawed 
only hours before transfusion into patients. Prochymal was found to have a viability of about 
70% upon thawing, but many believe that even the “live” cells are dysfunctional, with lowered 
metabolism and immunomodulatory capacity.54  
A final consideration is that MSCs are not immunosuppressive at baseline and only adopt 
this phenotype in response to instructive cues.23 Since clinical trials have used “naïve” MSCs, the 
therapeutic capacity reached by the cells is entirely dependent on an individual patient’s internal 
microenvironment. Compared to in-bred mice, humans show much greater biological variation, 
which may explain the lack of consistent benefit MSCs have shown in human clinical trials. A 
strategy that could potentially mitigate such variation would be to “prime” cells with instructive 
cues before injection. This could induce uniformly therapeutic cells, which would no longer rely 
on patient-specific in vivo cues. In further support of this notion, studies have shown that priming 
MSCs can also revitalize senescent cells to become usefully immunomodulatory again,55 
overcoming one of the previously listed obstacles. 
	 9	
1.4 Our Strategy 
1.4.1 Objective 
Considering the many ways by which priming MSCs could improve upon current therapies, our 
goal was to design an optimal in vitro priming regimen that could eventually be developed for 
testing in clinical trials. We first examined the microenvironmental cues common to biological 
scenarios where immune escape and immune tolerance are present, such as solid tumors.56–58 
Across diverse malignancies, hypoxia and inflammation are commonly present, suggesting that 
the combination of these two environmental cues may be ideal for inducing immunosuppressive 
cell phenotypes. In support of this notion, there have been several studies of priming MSCs with 
one of these two priming cues.22,59,60  
The pro-inflammatory cytokine interferon-γ (IFN-γ) has been the most extensively 
investigated factor for priming MSCs.22,23,61 Indeed, the International Society for Cellular 
Therapy (ISCT) recommends it as a standard priming method for evaluating the 
immunosuppressive capacity of MSCs in vitro, with induction of the tryptophan catabolizing 
enzyme indoleamine-2,3-dioxygenase (IDO) as a readout.23 In addition to IFN-γ, hypoxia 
priming has been shown to enhance the immunomodulatory capacity of MSCs, their ability to 
promote angiogenesis and tissue repair, and  survival in animal models of ischemia.59,62–64  
 
1.4.2 Hypothesis 
Based on the above observations, we hypothesized that combining IFN-γ and hypoxia priming 
would lead to MSCs that are more effective as an immunosuppressive cell therapy than if either 
cue were used alone. 
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1.4.3 Specific Aims 
We first sought to test our hypothesis by comparing how IFN-γ and hypoxia directly alter the 
immunomodulatory phenotype of MSCs. This led to our First Aim:  
 
Aim 1: To evaluate the effect of single vs. dual IFN-γ/hypoxia priming on the 
immunomodulatory capacity of MSCs 
 
However, the “therapeutic” quality of MSCs for treating immune and non-immune disorders 
depends on more than their anti-inflammatory features, as cell survival and homing also play 
important roles. We thus wanted to obtain a more comprehensive understanding of how various 
priming regimens altered the MSC phenotype. This led to our Second Aim: 
 
Aim 2: To conduct a global proteomic and metabolomic characterization of single vs. dual 
IFN-γ/hypoxia primed MSCs  
 
Finally, we sought to assess whether dual priming MSCs would lead to a significant 
improvement in their ability to treat GvHD. For these studies, we planned to use a well-
established xenogeneic mouse model of GvHD. We additionally wanted to leverage the skills of 
our lab to develop an ex vivo engineered model of GvHD of the skin, which is a model that is 
still in development. These aspirations are summarized in our Third Aim: 
	
Aim 3: To compare the ability of dual IFN-γ/hypoxia primed vs. unprimed MSCs to 









Methods for MSC Culture and Priming  
2.1 MSC line validation  
Frozen vials of MSCs from eight separate fully de-identified human lipoaspirates (LaCell, New 
Orleans, LA) were used in experiments. Given the trend towards using adipose-derived MSCs in 
clinical trials, we used cells from this source for our studies.12 However, many previous studies 
of MSC priming have used MSCs from alternative tissue sources9,11,13,16, and so we will retain 
the acronym “MSC” to emphasize the likely generalizability of our findings.  
Cell lines were initially tested for tri-lineage differentiation as well as positive expression 
of in vitro MSC surface markers. Adipogenic, chondrogenic, and osteogenic differentiation was 
performed as previously described.65 For immunophenotyping, MSCs were stained for standard 
MSC markers (CD29, CD73, CD90, CD105) as well as for HLA-DR, both before and after 
priming. Cells were stained in BD BSA Stain Buffer for 20 minutes at 4 °C and then washed 
twice in this same buffer. All data collection was performed on a BD FACS CANTOII flow 
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cytometer followed by analysis in FlowJo (Ashland, OR). Representative data from one of the 
most commonly used MSC lines is shown in Figure 3. MSC lines were also regularly tested to 
be mycoplasma negative (MycoAlert, Lonza). 	
	
Figure 3 (a) Demonstration of tri-lineage differentiation capacity of control adipose-derived MSCs. (b) Expression 
of MSC surface markers and HLA-DR upon exposure to different priming conditions. 





















































































































2.2 MSC culture and priming  
MSCs were expanded to P3 and cryopreserved. MSC expansion media consisted of high glucose 
DMEM 11965 (ThermoFisher), 10% FBS, and 1% Penicillin/Streptomycin. Cryopreservation 
media consisted of 50% MSC media, 40% FBS, and 10% DMSO. For a given experiment, P3 
vials were thawed, sub-cultured to P4 (seeding density 5,000 cells/cm2) and, upon near-
confluence, were either kept in control conditions or exposed to 1% O2 (New Brunswick Galaxy 
14S or 48R incubator), 25-100 ng/mL IFN-γ (Peprotech), or both conditions. Cells were then 
collected for characterization or functional assays, as shown in Figure 4. Regardless of priming 



















Figure 4 Experimental Design. Primed MSCs were evaluated for their ability to inhibit T-cells in MSC-mixed 
lymphocyte reaction co-cultures (MSC-MLR). To then discern the origin of group differences in 
immunosuppressive capacity, numerous mechanistic studies were pursued. 
 
2.3 Optimizing priming duration  
Initial pilot studies were conducted to determine the optimal duration of priming. First, two vs. 
four day priming regimens were compared. The fold increase in expression of six 
immunosuppressive genes upon dual IFN-γ/hypoxia priming was determined by polymerase 



















was deemed unnecessary to prime cells for longer than two days (Figure 5). 
 
Figure 5 Comparison of the fold increase (2-DDCt) in immunosuppressive gene expression in dual primed over 
control MSCs using a two-day vs. four-day priming regimen.  	
The gene most highly induced at day two was indoleamine-2,3-dioxygenase (IDO). Since this 
protein is thought to be very important for MSC function,23 the kinetics of IDO upregulation 
were subsequently tracked by both PCR and flow cytometry (Figure 6a and b).  
	
Figure 6 IDO onset kinetics. MSCs were exposed to dual IFN-γ/hypoxia for different durations before samples were 
collected for (a) PCR analysis and (b) flow cytometry analysis.  
While significant induction occurred by 8-12 hours of exposure, expression levels were 
still higher from 48 hours of priming. For this reason, a 48-hour priming regimen was chosen for 


































































































































































































































































































































































































































































































































































































































































































































































































Aim 1: To evaluate the effect of single vs. dual IFN-γ/hypoxia 
priming on the immunomodulatory capacity of MSCs 
3.1 Overview 
In the literature, the notion of “licensing” or priming MSCs towards an immunosuppressive 
phenotype is almost exclusively done with pro-inflammatory cytokines.66–68 While some studies 
have used TNF-a, LPS, or other toll-like receptor agonists to accomplish this feat, the most 
commonly cited method is to use IFN-γ.22,23 Nevertheless, there are a growing number of studies 
focusing on the potential benefits of hypoxia for MSC therapies. For example, some describe its 
ability to promote a more primitive MSC phenotype in the long term, enabling MSCs to better 
maintain their stemness and avoid senescence as they are expanded to clinically relevant 
numbers.69 Other studies have shown a survival benefit to hypoxia preconditioning, as it appears 
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to prolong the lifespan of MSCs injected into animal models of ischemia.70,71 However, few 
studies have explicitly focused on how hypoxia affects the immunosuppressive function of 
MSCs,72,73 even though there is reason to believe this might be true. 
 Two of the best natural examples of immune escape and tolerance are solid-tumors and 
the maternal-fetal interface.74,75 In addition to the presence of inflammatory cells, these 
physiological states demonstrate a low oxygen tension. Because tumors often grow at a faster 
pace than their neovasculature, they tend to have hypoxic cores.57 Hypoxia is also characteristic 
of the first trimester of pregnancy.76 It thus seems plausible that hypoxia supports survival and 
growth in these settings by helping to prevent immune attack. Mechanistically, some studies 
have suggested a correlation between hypoxia and anti-inflammatory macrophages.77 Others 
have implicated hypoxia in the upregulation of HLA-G, an immune tolerance promoting protein 
found in both biological scenarios. MSCs are also known to be able to express HLA-G, and the 
confluence of these observations led us to suspect that hypoxia preconditioning of MSCs may do 
more than just influence their stemness and survival skills in vivo – it could also directly impact 
their immunomodulatory capacity. Our first aim was thus to determine if – as with IFN-γ – 
hypoxia could induce an immunosuppressive phenotype in MSCs, and if so, whether combining 
both cues would yield even more potent immunosuppression.    
 
3.2 Materials and Methods 
3.2.1 Mixed lymphocyte reactions (MLRs)  
For MLRs, a peripheral blood mononuclear cell (PBMC) cryo-bank was made using fully de-
identified samples from 10 different donors, to generate different sets of stimulator-responder 
pairs. PBMCs were isolated from fresh leukopaks (New York Blood Center, New York, NY) 
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using Histopaque-1077 (Sigma, St. Louis, MO) based on density gradient centrifugation, washed 
twice with bone marrow medium (BMM; Media 199 (Thermo Fisher) containing 1% HEPES, 
1% Penicillin/Streptomycin, and 20 kU DNAse I (Sigma), treated with ACK lysis buffer 
(Thermo Fisher) for red cell lysis, and cryopreserved.  
MSCs were trypsinized after 48-hour priming and seeded at either 1 × 106/mL or 2 × 
106/mL in 40 µL (i.e. 40,000 or 80,000 cells total) in 96-well U-bottom plates in complete AIM-
V (Thermo Fisher) supplemented with 5% heat-inactivated human AB serum (Sigma), 1% 
Penicillin/Streptomycin, 1% HEPES, and 50 µM 2-mercaptoethanol (cAIM-V). Two batches of 
allogeneic PBMCs were thawed in 1:1 BMM:cAIM-V and washed twice. Responder PBMCs 
were stained with BD Violet Proliferation Dye (Becton Dickson (BD) Canaan, CT) per 
manufacturer’s instructions (final concentration: 1 µM). Stimulator PBMCs were inactivated 
using 30 Gy X-ray irradiation with an X-RAD 320 irradiator (Precision X-ray Inc., North 
Branford, CT) or 10 mg/mL Mitomycin C (always provided similar results in comparison 
studies). Stimulator and responder PBMC cell concentrations were adjusted to 2.5 × 106/mL, and 
80 µL of each cell suspension (i.e. 200,000 cells) was layered on top of previously plated MSCs. 
Thus, the stimulator to responder ratio was 1:1 and the MSC to responder ratio was 1:2.5 or 1:5. 
MLR experiments were run for 5 days, with 50 µL of cAIM-V added halfway through. 
For end-point analysis, two antibody panels were used: CD3/4/8/25/107a 
(activation/cytotoxicity) and CD3/4/45RA and CCR7 (naïve vs. memory). Primary conjugated 
antibodies (BD) were used at the recommended test size, except for CD4 and CD8, which were 
used at 1:80 and 1:40 dilutions, respectively (see supp. Table S1 for clones). All surface staining 
was done without fixation in BD BSA Stain buffer. Flow cytometry analysis was done within 30 
minutes of staining. When analyzing CD4+ and CD8+ subpopulations, each group was 
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normalized to that of the MLR with no MSCs (positive control set to 100%) by dividing each 
experiment’s % divided (violet negative), % CD25+, or % CD107+ by the corresponding values 
for the MLR only condition. These group data were then averaged over 7-11 experiments. 
For some experiments, extra MLR-MSC reactions were set up for various Day 1 and Day 
3 analyses. Pro-inflammatory cytokine levels were detected using a Human Cytokine 16-Plex 
ELISA kit (PBL Assay Science, Piscataway, NJ). Supernatant glucose levels were determined by 
the Hormone and Metabolite Core Laboratory at Columbia University Medical Center. 
Supernatant lactate levels were determined by the colorimetric L-Lactate Assay Kit (Abcam, 
Cambridge, MA), following an initial deproteinization step (as instructed) and dilution 1:3 to be 
within the range of the kit.  Cells from Day 1 and Day 3 MSC-MLR experiments were also 
collected, fixed, permeabilized, and stained for the GLUT1 transporter. 
 
3.2.2 qRT-PCR  
A list of 15 genes implicated in MSC-based immunosuppression/protection was established 
based on published studies (primers shown in Table S2).16,28,78–83 MSC priming experiments 
were repeated 4 times using MSCs from 3 different donors. RNA was isolated using the 
RNAqueous Micro Kit (Thermo Fisher) and quantified using a Nanodrop ND1000 (Wilmington, 
DE). RNA was treated with DNase I, Amplification Grade Kit (Thermo Fisher) and converted to 
cDNA using the High Capacity cDNA Reverse Transcription Kit (Thermo Fisher). qRT-PCR 
analysis was performed using 20 ng cDNA per reaction and SYBR Green Master Mix (Thermo 
Fisher). The expression of target genes at each time point was normalized to GAPDH, which has 
been shown to be robust as a housekeeping gene for MSCs in hypoxic conditions,84 and 
subsequently to the unprimed phenotype at its baseline time point (2−ΔΔCt).  
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3.2.3 IDO activity assay  
MSCs that had just been primed for 48 hours were re-plated in fresh control MSC media at 
10,000 cells per well in 96-well plates and left overnight to attach. Measurement of IDO activity 
was achieved via a kit (BPS Bioscience, San Diego, CA) as per the manufacturer’s protocol, with 
the modification that no transfection of IDO was performed, and it was simply measured in the 
MSCs of different priming conditions. Samples were performed in replicates of 6. 
 
3.2.4 HLA-G Western blot  
After washing twice with PBS, primed MSCs were lysed on ice for 30 minutes with NP-40 Lysis 
buffer containing phosphatase and protease inhibitors each at a 1:50 ratio (Thermo Fisher). 
Lysates were centrifuged at 4 °C, 13,600 × g for 15 minutes. Protein concentrations were 
determined via a BCA protein assay (Thermo Fisher). After the protein concentrations from 
different MSC priming groups were normalized, the supernatant was diluted 1:1 with 2x 
Laemmli Sample Buffer (Bio-Rad, Hercules, CA) and boiled at 95 °C for 5 minutes. Protein 
samples were resolved by SDS-PAGE in a 4–20% precast polyacrylamide gel (Bio-Rad) and 
electrotransferred onto a polyvinylidene difluoride membrane. After transfer, the membrane was 
blocked with 5% BSA TBST for 1 hour and probed with anti-HLA-G primary antibody (1:500; 
OriGene Technologies) at 4 °C overnight. The membrane was then washed with TBST x3 and 
exposed to goat anti-rabbit IgG AlexaFluor 680 secondary antibody (1:10,000; Thermo Fisher) 
for 1 hour. The membrane was then imaged on a Licor Odyssey scanner (Lincoln, NE). 
 
 
3.2.5 Flow cytometry for functional proteins  
MSCs were stained for immunomodulatory proteins that had shown up-regulation at the  
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mRNA level from qRT-PCR (HLA-G, COX-2, IDO, PD-L1, HLA-E; also GLUT1 for metabolic 
studies). For intracellular proteins, cells were fixed, permeabilized and stained using the reagents 
in the BD Cytofix/Cytoperm kit. For surface staining, cells were stained in BD BSA Stain Buffer 
for 20 minutes at 4 °C and then washed twice with stain buffer. All data collection was 
performed on a BD FACS CANTOII flow cytometer followed by analysis in FlowJo. A 
complete list of antibody clones and dilutions can be found in Table S1.  
 
3.2.6 HGF ELISA  
MSC supernatant collected at the end of 48 hour priming was collected, spun down to pellet cell 
debris, and then transferred to fresh tubes for storage at -80 °C. ELISA samples were brought to 
room temperature and used undiluted with the Invitrogen Human HGF ELISA kit (Carlsbad, 
CA), as per manufacturer’s instructions.  
 
3.2.7 Seahorse assays  
Seahorse assays were conducted to determine whether priming affected MSC metabolism, as this 
could possibly explain differences in immune modulatory capacity. Differently primed MSCs 
were plated on Seahorse tissue culture plates (10,000 cells in 100 µL) and incubated overnight at 
37 °C in a standard 5 % CO2 incubator. The following day, wells were washed twice with 
Seahorse Assay medium (100 mL) containing (1 mL of 200 mM L-glutamine, 1 mL of 100 mM 
Sodium Pyruvate, and 400 µL of 45% D-Glucose; pH 7.4) and the plate was kept in a non-CO2 
incubator for 2 hours prior to running the MitoStress Assay (Oligomycin 1 µM, FCCP 1 µM, 
Rotenone/Antimycin 1 µM). Data were analyzed using Wave (Agilent, Santa Clara, CA). 
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3.2.8 Lactic acid titration  
PBMCs were thawed, as previously described, and stained in HEPES-buffered saline at 37 °C 
for 30 minutes with pHrodo® Red AM (Thermo Fisher) as per manufacturer’s instructions 
(1000x dilution of dye). After a single wash with HEPES buffer, samples were divided into 5 
eppendorf tubes, spun down, and resuspended in cAIM-V with L-lactic acid (Sigma) added to 
make concentrations of: 0 mM, 5 mM, 10 mM, 20 mM, and 30 mM. Cells were resuspended in 
these new media and incubated at 37 °C for 30 minutes. Immediately prior to each flow 
cytometry reading, each sample was diluted 1:9 with BD Stain Buffer and mixed well. This 
neutralized external pH and diluted media components without permitting time for intracellular 
lactate to be exported. For lymphocyte proliferation experiments, PBMCs were thawed and 
stained with BD Violet Proliferation dye, as described previously, and resuspended in cAIM-V 
with L-lactic acid added to the concentrations above. Cells were plated in 96-well U-bottom 
plates at 200,000 cells per well. Concanavalin A was added to be 5 µg/mL, and PBMCs were 
analyzed by flow cytometry on Day 3. 
 
3.2.9 Mass spectrometry  
MSC plates were washed x3 with ice-cold PBS to remove residual FBS and added cytokines. 
Lysis buffer consisting of TBS with 3% SDS and 50 µL protease inhibitors (Sigma) was added to 
each MSC plate. The lysate was collected and proteins were precipitated in 
chloroform/methanol. Mass spectrometry was performed at the Quantitative Proteomics and 
Metabolomics Center at Columbia University with an UltiMate 3000 RSLCNano ultrapressure 
liquid chromatograph coupled to a Q Exactive HF (Orbitrap) mass spectrometer. 
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3.2.10 Statistical analysis  
One-way ANOVA analysis in conjunction with Tukey post-hoc tests was used to compare the 
MLR, PCR, Flow cytometry, ELISA, glucose, and lactate results from different priming groups 
using GraphPad Prism 6 software (La Jolla, CA). Data were presented as mean ± standard 
deviation, and a p value <0.05 was considered statistically significant. 
 
3.3 Results 
3.3.1 MSC priming with IFN-γ or hypoxia leads to similar improvements in T-cell inhibition over 
control MSCs, while dual primed MSCs show twice the functional improvement  
Addition of control MSCs to MLRs resulted in mild inhibition of both CD4+ and CD8+ T cell 
proliferation (% Divided) and activation (% CD25+) at Day 5 of MSC-MLR co-cultures (Figure 
7a & 7b). When IFN-γ or hypoxia primed MSCs were instead used, MSCs were consistently 
~25-30% more effective at inhibiting proliferation and activation of CD4+ T-cells (i.e. 
determined by % divided primed MSCs/% divided C MSCs), and ~20% more effective at 
inhibiting CD8+ T-cells. This inhibitory advantage approximately doubled for MLRs with dual-
primed MSCs. Doubling the dose of MSCs by using a 1:2.5 MSC:PBMC ratio led to greater T-
cell inhibition regardless of priming regimen, although the relative inhibitory capacities amongst 
the priming groups were notably maintained. Dual primed MSCs also showed significantly 
greater inhibition of CD8+ T-cell cytotoxicity (%CD107+) compared to control MSCs, although 
this was only seen at the 1:5 MSC:PBMC ratio.  
The effect of MSC:MLR co-culture on differentiation of responding T cells was studied 
by analyzing the expression of CCR7 and CD45RA. By day 5, the responder-only group 
(negative control; no allogeneic PBMCs present) had 48% of the CD4+ T cells in the naïve sub- 
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Figure 7 End-point analyses for MSC-MLR co-culture. The variable inhibition by control (black) and primed 
MSCs (colored) is evident by comparing their violet- population (% divided) to that of the MLR alone condition (set 
to 100% division) at day 5. T-cell activation status (% CD25+) and cytotoxic capacity (% CD107+) were similarly 
determined at day 5. (a) Shows activation and proliferation data for the CD4+ T-cell fraction. (b) Shows these same 
data for the CD8+ T-cell fraction. (c) Representative memory panel data for the CD4 subset at Day 5 of an MLR-
MSC co-culture study. The “responder only” group was a negative control that lacked allogeneic stimulator PBMCs. 
N:naïve; CM: central memory; EM: effector memory; TEMRA; terminal effector; n = 7-11 p < 0.05 *, < 0.01 **, < 
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-set (CCR7+CD45RA+), while the MLR (positive control) had only 15.7% cells in this subset. 
Co-culture with MSCs inhibited the loss of naïve phenotype (Figure 7c), as 24.7%, 31%, 33.5%, 
and 39.3% of the responding CD4+ T-cells remained in the naïve subset after co-culture with C 
MSCs, I MSCs, H MSCs, and D MSCs, respectively. These differences in the naïve fraction 
reflected a shift from the central memory T-cell compartment, as the central memory fraction 
decreased as the naïve fraction increased. 
To investigate how early in the MSC-MLR experiments T-cells exhibited different 
activation patterns, we looked at two indicators of T-cell activation that preceded the end-point 
analysis at Day 5 (i.e. % division): GLUT1 expression and pro-inflammatory cytokine levels in 
the supernatant. The glucose transporter, GLUT1, is upregulated in activated T-cells to fuel 
glycolysis. As expected, T-cells in the MLR (no MSCs) condition did not upregulate GLUT1 
over the responder-only group until Day 3, reflecting slow activation (Figure 8a, supp. Table 
S3). When MLRs were instead co-cultured with MSCs, there was a rapid increase in T-cell 
GLUT1 expression even at Day 1, likely due to the T-cells sensing competition for resources. 
Nevertheless, at Day 1 and Day 3, there were differences depending on the MSC priming 
condition. While single-primed MSCs led to less T-cell GLUT1 expression than control MSCs, 
dual-primed MSCs were associated with significantly lower T-cell GLUT1 expression levels 
than all other MSC conditions. Indeed, at Day 1 they were not significantly different from the 
responder-only group, and they were still the most similar to this group by Day 3. Differences in 
pro-inflammatory cytokine levels were only apparent by Day 3 (Figure 8b), and MSC-MLRs 
with dual-primed MSCs had lower levels than single-primed MSCs. MLRs with control MSCs 
had higher supernatant concentrations of pro-inflammatory cytokines than MLRs without MSCs, 
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suggestive of an initial allogeneicity. However, the control MSCs were still inhibitory in MLRs, 
possibly due to an immunosuppressive reactivity to the pro-inflammatory milieu that developed.     
	
Figure 8 Early and mid-point analyses for MSC-MLR co-culture. (a) GLUT1 expression in CD4+ and CD8+ T-
cells at Day 1 and Day 3 of MSC-MLR co-cultures. The mean ± SD intensity data can be found in Table S3 of the 
SI (significance determined by ANOVA analysis). (b) Pro-inflammatory cytokine levels measured at Day 1 and 3 of 
MSC-MLR co-cultures. All pairwise comparisons were significant except where indicated. Cytokine concentrations 
for the responder only group were below the detection limit and are thus not shown. n = 4  
 
3.3.2 IFN-γ and hypoxia priming differentially upregulate immunomodulatory genes  
To uncover how IFN-γ and hypoxia enhanced MSC immunosuppression, both as individual 
priming cues and in combination, we conducted qRT-PCR for 15 genes previously implicated in 
MSC-based immunosuppression (Figure 9). IFN-γ priming led to >5-fold induction of HLA-G, 
HLA-E, HGF, iNOS, and, most markedly, PD-L1 and IDO, which were induced by 730-fold and 
31,000-fold, respectively. In contrast, hypoxia priming led to greater induction of HLA-G than 
IFN-γ priming (102 fold vs. 5 fold) and induction of COX-2.  
Overall, the combination of the two priming conditions resulted in an amalgamation of 
the two transcriptional upregulation patterns obtained by IFN-γ and hypoxia individually. The 
effects were not precisely additive, as the expression of some genes (e.g. IDO, HLA-E, PD-L1) 
Day 1 Day 3 Day 1 Day 3
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induced by IFN-γ was partially subdued by dual priming, while the induction of HLA-G was 
instead potentiated.  
	
3.3.3	 Genes	 upregulated	 by	 dual	 priming	 at	 the	 mRNA	 level	 show	 strong	 induction	 at	 the	
protein	level		
We next investigated the mRNA trends from MSC priming at the protein level. Some trends 
were confirmed. For example, HGF protein was only detectable in the supernatant of IFN-γ-
primed cells, (Figure S1). Notably, PD-L1, IDO, and HLA-E, which had less mRNA induction 
from dual priming than from IFN-γ priming, showed similar or greater induction by dual priming 
(Figure 10a, Table S4). In fact, IDO protein expression was significantly greater after dual 
priming than after exposure to IFN-γ alone. This unanticipated result was confirmed by an IDO 
activity assay (Figure 10b), where dual-primed MSCs showed significant enhancement of IDO 
activity over IFN-γ-primed MSCs.  
IFN-γ Hypoxia Dual
IDO 31,000 0.730 18,100 abc
HLA-G 5.24 97.5 207 abc
HLA-E 83.5 0.850 30.1 ab
TGF-β 1.87 0.890 0.890 ab
IL-10 1.55 0.970 0.930
HGF 10.1 0.300 2.86 ab
LIF 1.86 1.51 1.26
COX2 2.43 7.95 3.18 ac
iNOS 12.1 0.514 10.3 a
TSG-6 0.230 0.290 0.0700 bc
CD59 1.89 0.770 1.08 ab
PD-L1 730 1.05 162 ab
ARG-1 0.380 0.640 0.500
GAL-1 2.02 0.900 1.07 ab
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TSG-6 0.230 0.290 0.0700 bc
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PD-L1 730 1.05 162 ab
ARG-1 0.380 0.640 0.500
GAL-1 2.02 0.900 1.07 ab
GAL-3 1.46 0.400 0.480 ab
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Figure 9 Differential expression of genes 
related to immunosuppression after 48 hours 
of single or dual priming. mRNA data obtained 
by qRT-PCR are shown after 48 hours of 
priming by IFN-γ, hypoxia, or dual IFN-
γ/hypoxia in a representative experiment. Data 
are normalized to the expression in control 
MSCs (normoxia and regular MSC media). The 
color bar scales the fold difference from 0.01 to 
100 (and saturates at either end). Significant 
differences between groups, as determined by 
ANOVA and Tukey post-hoc tests (p < 0.05), 
are shown at the right of each gene as indicated: 
(a) for IFN-γ vs. hypoxia stimulation, (b) for 
IFN-γ vs. dual stimulation, and (c) for hypoxia 
vs. dual stimulation. n = 4-6 	
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Enhancement of the two genes induced by hypoxia at the mRNA level (COX-2 and 
HLA-G) was analyzed by flow cytometry. COX-2 protein expression was equally enhanced by 
all priming regimens, and protein levels were only slightly greater than those for control MSCs. 
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c HLA-G Western Blot
a
Figure 10 Protein expression after 48 hours of single or dual priming. (a) Histograms are shown from a 
representative experiment with 20,000 events (same experiment conducted n = 3 times). All pairwise 
comparisons for IDO, HLA-G, HLA-E, and PD-L1 were significant except control vs. hypoxia (p<0.0001). 
By contrast, only control vs. hypoxia was significant for COX-2 (p<0.01). (b) Relative IDO activity in 
MSCs replated after 48 hours of different priming regimens. IDO activity corresponds to detecting the 
tryptophan byproduct kynurenine via absorbance at 480 nm. 6 wells were averaged per condition. (c) 
Western blot showing relative HLA-G protein levels in MSC lysate after 48-hours of different priming 
regimens. Each lane was initially loaded with the same amount of protein (per BCA assay). p<0.0001 **** 
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While MSC HLA-G protein levels were the greatest after dual priming, consistent with the PCR 
data, protein levels were greater from priming by IFN-γ than by hypoxia, opposite to the PCR 
findings. This result was confirmed by Western blot analysis, which showed that HLA-G was 
substantively induced by both IFN-γ and dual priming at the protein level (but not by hypoxia) 
(Figure 10c). Thus, an important overall finding was that hypoxia did not upregulate any of the 
studied immunosuppressive proteins more than IFN-γ. 
 
3.3.4 Hypoxia and dual priming induce a metabolic shift to glycolysis  
We next explored possible metabolic explanations for hypoxia-induced immunosuppression by 
investigating how different priming regimens affected major metabolic pathways in MSCs.  
	
 
Figure 11 Influence of MSC priming on cell metabolism. (a) After 48 hours of priming, MSCs were replated at 
10,000 cells per well into Seahorse Tissue Culture plates and evaluated by the Seahorse Mitostress kit. n=5 (b) 
GLUT1 expression in MSCs after 48 hours of priming. (c) Glucose and lactate levels in MSC-MLR co-culture 
experiments at Day 1 and Day 3. n = 2. All pairwise comparisons are significant at p<0.001 except where indicated 
(note: error bars for glucose graph are so small they are often not visible).  
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IFN-γ-primed MSCs had the highest oxygen consumption rate (OCR, by Seahorse Analysis), 
which is a marker for oxidative phosphorylation. The OCR decreased from control MSCs to 
dual-primed MSCs and was lowest for hypoxia-primed MSCs (Figure 11a). Importantly, while 
hypoxia-primed and dual-primed MSCs had a reduced OCR relative to MSCs not exposed to 
hypoxia, they both had a significantly higher extracellular acidification rate (ECAR), which is a 
metric for glycolytic metabolism (acid from lactate production). The shift towards glycolysis in 
hypoxia-primed and dual-primed MSCs was further supported by unique upregulation of 
GLUT1, the inducible glucose transporter also required for T-cell glycolysis (Figure 11b).  
We then investigated if the observed metabolic changes could explain the trends seen in 
the MSC-MLR co-cultures (Figure 7), specifically (i) why hypoxia-primed MSCs were as 
inhibitory as IFN-γ-primed MSCs and (ii) if metabolic changes could explain the additive 
immunosuppressive efficacy of dual-primed MSCs. Glucose and lactate levels were measured at 
Days 1 and 3, time points that precede T-cell division (to maintain consistent cell numbers 
amongst groups) but during which T cells may become activated. As expected, by Day 3, 
activated PBMCs in the MLR (no MSCs) had higher glucose consumption than the responder 
only group, and they further showed a trend suggestive of higher lactate production, although 
this difference was not significant (Figure 6c). Addition of MSCs had a large influence on 
glucose and lactate levels. Dual-primed and hypoxia-primed MSCs led to the greatest glucose 
depletion and lactate production by Day 1, consistent with higher GLUT1 expression and 
induction of glycolysis. Notably, dual-primed and hypoxia-primed MSCs led to a 3-fold and 2-
fold, respectively, increase of lactate in the supernatant relative to control MSCs (~15 mM and 
10 mM vs. 5 mM). Glucose levels continued to decline between Days 1 and 3, while the rate of 
consumption during this phase was similar amongst MSC-MLR groups (drop of ~40 mg/dL for 
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control, IFN-γ and hypoxia-primed MSC-MLR co-cultures; 45 mg/dL for dual-primed; Table 
S4). Lactate accumulation started to plateau between Days 1 and 3, although the highest levels 
were still found in MSC-MLR reactions with dual-primed MSCs.  
To explore the consequences of a high extracellular lactate concentration, we looked at its 
effect on intracellular pH (pHi) and proliferation of T-cells in titration experiments. Increasing 
extracellular lactic acid levels in fresh cAIM-V media (see Methods) led to a dose-dependent 
drop in T-cell pHi, which started to become pronounced at 15 mM, and by 30 mM, dropped 
dramatically along with media pH (Figure 12a; Table S6).  
	
Figure 12 Effect of external lactate concentration on PBMCs (a) Effect of external L-lactic acid concentration on 
intracellular pH as revealed by increasing pHrodo Red dye intensity with declining pH. Representative overlay 
shown for n = 3 (b) Change in ungated PBMC scatter properties as the external L-lactic acid concentration reaches 
30 mM. The shift is suggestive of dying cells. (c & d) Effect of lactic acid concentration on T-cell division in 
response to Concanavalin A. n = 3. “Negative control” in the legend refers to unstained cells for (c) and 
unstimulated cells for (d). 
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As the lactic acid concentration increased from 20 mM to 30 mM, there was also a notable 
change in the scatter properties of the T-cells, consistent with cells undergoing apoptosis (Figure 
12b). Titrating lactic acid into the media also attenuated both CD4+ and CD8+ T-cell division in 
response to the strong mitogen Concanavalin A (Figure 12c & d). At 10 mM lactate, T-cell 
division was reduced to 30-45% of the maximum rate, and at 15 mM, T-cell division was almost 
completely eliminated (Figure 12c & d). 
 
3.3.5 Mass spectrometry confirms that hypoxia influences MSC metabolism but does not 
upregulate proteins with direct immunosuppressive capacity  
To further evaluate our metabolic hypothesis for hypoxia-induced MSC immunosuppression and 
for why dual-primed MSCs showed additive improvements in immunosuppression compared to 
single priming, mass spectrometry was performed. This was to confirm that cells exposed to 
hypoxia did not upregulate any proteins with immunosuppressive capacity that were missed on 
PCR or flow cytometry analysis.  
Proteins that changed in expression due to hypoxia priming were predominantly 
mitochondrial proteins that had a role in cellular metabolism. Specifically, proteins involved in 
oxidative phosphorylation and the citric acid (TCA) cycle were down-regulated, as were 
mitochondrial ribosomal proteins. When STRING analysis was performed on the list of proteins 
that changed over 2-fold from hypoxia priming (over control MSCs), it did not associate any 
proteins with immunomodulation.  
Dual primed cells showed similar changes in the metabolic pathways altered by hypoxia 
alone, although in some instances, a protein was downregulated slightly less than 2-fold such that 
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there was not 100% overlap in the list of downregulated proteins between hypoxia and dual 
primed cells (Table 2). 
Table 2 STRING analysis of pathways altered by hypoxia primed or dual primed MSCs relative to control MSCs.	
Hypoxia Primed 
pathway ID pathway description protein count false discovery rate 
GO.0032543 mitochondrial translation 18 4.93E-16 
GO.0006119 oxidative phosphorylation 16 1.52E-16 
GO.0072350 tricarboxylic acid metabolic process 7 2.27E-06 
Dual Primed  
pathway ID pathway description protein count false discovery rate 
GO.0032543 mitochondrial translation 16 2.79E-07 
GO.0006119 oxidative phosphorylation 11 3.08E-05 
GO.0072350 tricarboxylic acid metabolic process 7 6.20E-04 
 
3.4 Discussion 
Studies from the last decade have revealed that MSCs are not immunosuppressive at baseline but 
must be induced to adopt this phenotype by environmental cues like inflammatory cytokines. 
Nevertheless, clinical trials to-date have used naïve MSCs (called “control” MSCs in this paper). 
In support of this approach, MSCs are often tested for treatment of inflammatory conditions, and 
they may experience relevant priming cues after they have been injected. However, the down 
side is that cells experience variable induction based on the specific patient and disease, with a 
delay in the onset of their therapeutic effect. Given that MSCs are thought to have a short 
lifespan in vivo (hit-and-run hypothesis),16,19,20 a significant fraction of their therapeutic 
opportunity may be cut out by having to be primed only after injection, and it may limit their 
ability to be used preventatively in situations where inflammation has not fully developed. 
 For the above reasons, our main objective was to better define and characterize an 
optimal MSC priming regimen in vitro. While IFN-γ is a common priming cue, we hypothesized 
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based on the cancer (i.e. tumor immune escape) and MSC literature that adding hypoxia would 
lead to even more effective MSCs and sought to compare these two priming cues side-by-side 
and in combination. Our central findings were that IFN-γ and hypoxia priming led to MSCs that 
were equally more effective at inhibiting T-cell division than unprimed MSCs, and that using 
both cues together had an additive effect, with dual-primed MSCs showing twice the 
improvement in immunosuppressive capacity than single priming alone. 
To better understand how MSC priming influenced initial T-cell activation, we measured 
CD25 expression, which was suppressed in a similar pattern to T-cell division across the 
different MSC priming groups. When combined with the findings that dual-primed MSC-MLRs 
were correlated with the largest remaining naïve T-cell population, the lowest Day 1 and 3 pro-
inflammatory cytokine levels, and the lowest induction of T-cell GLUT1 expression, this 
suggests that T-cell division was best impaired in this experimental group because fewer T-cells 
became activated in the first place.   
 We next sought to understand the mechanisms through which dual primed MSCs 
mediated their effects. Initial PCR data suggested that each priming cue upregulated distinct 
immunosuppressive genes, with IFN-γ primarily inducing IDO and PD-L1, and hypoxia 
inducing HLA-G and COX-2. However, when we explored these upregulated genes at the 
protein level, we saw different patterns. Notably, protein level expression of IDO was 
consistently superior in dual primed cells compared to IFN-γ alone. This contrasted with less 
induction of IDO in dual vs. IFN-γ primed cells at the mRNA level. Since hypoxia did not 
upregulate IDO at the protein level, this suggests a synergistic post-transcriptional interaction 
between IFN-γ and hypoxia signaling that was not predictable from our PCR studies. HLA-G 
protein also showed the highest induction from dual priming, which was consistent with PCR 
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data, but curiously, it was better enhanced by IFN-γ alone vs. hypoxia alone, differing from the 
PCR results. HLA-G upregulation by hypoxia at the mRNA level has been reported previously,56 
as has its extensive post-transcriptional regulation,85 which may explain the observed mRNA to 
protein level discrepancy. Of final note, COX-2 protein was similarly induced by the different 
priming regimens.  
 The protein level findings presented a problem with our initial mechanistic assumptions. 
One could attribute the superiority of dual priming to its promotion of the highest expression of 
immunosuppressive proteins, with similar PD-L1 and COX-2 expression to IFN-γ priming alone, 
and slightly higher HLA-G and IDO expression. However, these findings do not explain why 
hypoxia alone, which failed to induce any of these factors more than IFN-γ at the protein level, 
was equally as efficacious as IFN-γ at producing inhibitory MSCs in our MSC-MLR functional 
assays.  
 Referring back to the tumor literature, we were inspired to investigate a possible 
metabolic mechanism. Solid tumors use aerobic glycolysis for metabolism, which leads to rapid 
glucose consumption and lactate production.86 Glucose deprivation itself has been shown to limit 
T-cell division, as T-cells also use aerobic glycolysis and have high glucose demand.87 The 
buildup of local lactate concentrations in tumors (up to 40 mM) can also directly promote anti-
inflammatory immune cell phenotypes, limit T-cell cytotoxicity and division, and destroy intra- 
to extracellular lactate gradients such that the pH of the cell becomes acidic.88  
We postulated that hypoxia priming of MSCs could lead to similar metabolic-based 
inhibition pathways. We confirmed that hypoxic exposure shifts MSC metabolism towards 
glycolysis and that hypoxia and dual primed MSCs rapidly deplete glucose and produce lactate 
within one day of MSC-MLR co-culture. While media lactate levels appeared to eventually 
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saturate across the different MSC groups, Day 1 levels were approximately 2-fold higher for 
hypoxia-primed MSCs and 3-fold higher for dual-primed MSCs compared to MSCs maintained 
under control conditions. These different concentrations impacted pHi and T-cell division in L-
lactic acid titration experiments. Studies by others have shown that L-lactic acid concentrations 
of 15 mM and 10 mM correspond to a pHi of 6.25 and 6.8, respectively.88 As with our study, a 
dose-dependent inhibition of T-cells was found, with greatly impaired division once lactate 
concentrations exceeded 10 mM. Given that our hypoxia-primed and dual-primed MSCs 
produced these high lactate concentrations by Day 1 in MSC-MLRs, we propose that the high 
media lactate immediately influenced T-cell fate, as supported by the lower Day 1 T-cell GLUT1 
expression and the higher Day 5 naïve fraction compared to control MSCs.  
While the confluence of the PCR, flow cytometry, and metabolic studies lent support to 
this metabolic hypothesis for hypoxia-induced MSC immunosuppression, we did not exclude the 
possibility that hypoxia could have upregulated an immunomodulatory protein that we did not 
analyze at the mRNA or protein level. We thus pursued mass spectrometry to compare the 
proteome of MSCs exposed to the different priming conditions. In support of our metabolic 
theory, proteins that changed in expression from hypoxia priming (vs. control MSCs) were not 
associated with any immune pathways as per STRING analysis. This bioinformatics analysis did, 
however, demonstrate that most proteins that changed in expression were found in the 
mitochondria and were involved in metabolism. Specifically, pathways related to aerobic 
respiration – the TCA cycle and oxidative phosphorylation – were both downregulated, 
consistent with our previous findings that hypoxia priming shifted metabolism towards 
glycolysis. Similar pathway findings were also found in dual primed MSCs, likely contributing 
to their superior immunosuppressive capacity. 
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Cell-specific metabolic pathways have recently generated excitement as new targets for 
blocking cancer immune escape, but they could alternatively be opportunities for promoting 
immune suppression and tolerance. Indeed, one group has already explored using inhibitors of 
glycolysis to inhibit T-cell mediated allorejection in organ transplantation.89 We propose that 
hypoxia and dual primed MSCs could provide a similar function, by outcompeting T-cells for 
glucose and inhibiting them via high lactate levels.  
When MSCs are injected intravenously, they are unlikely to reach the high lactate 
concentrations seen in our experiments due to buffering by the blood; while tumors can reach 
levels up to 40 mM, blood levels >4 mM are considered “lactic acidosis”. However, MSCs are 
known to quickly home to inflammatory sites where they could more readily influence the local 
metabolic environment.30 This could also be accomplished via local injection of MSCs and MSC 
spheroids,90,91 which is being explored for local tissue repair and for protection of co-
transplanted allogeneic cells.92,93 Spheroidal formulation would also have the advantage of 
potentiating the metabolic shift towards glycolysis, as studies have shown that both the central 
hypoxic core and signaling from the 3D architecture itself promotes a glycolytic phenotype.42  
As a final consideration, “oxygen consuming” hydrogels have recently been designed, 
which maintain a local hypoxic environment for encapsulated cells that could also promote 
extended glycolytic metabolism.94 Considering there have been several published reports of IFN-
γ containing biomaterials, it seems feasible that our dual priming regimen could thus be 
formulated for local injection by encapsulating cells in IFN-γ functionalized aggregates or low 
oxygen hydrogels.95–98 
While the benefits of our priming regimen need to be tested in vivo, we believe that this 
initial, strictly in vitro, assessment is valuable in terms of elucidating how MSCs react to 
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microenvironmental factors that can enhance their therapeutic capacity. Given that hypoxia and 
inflammation often occur together in acute trauma and chronic disease, mechanisms described 
for our dual priming regimen may also better represent the functional changes in MSCs that are 
introduced into these pathophysiological situations.99,100  
In summary, we have compared two microenvironmental cues common to known 
situations of immune escape (e.g. tumors, maternal-fetal interface): IFN-γ and hypoxia, and 
demonstrated that they elicit distinctly different mechanisms of immune suppression in MSCs. 
We show that combining these separate pathways by exposure of MSCs to both priming cues 
leads to additive immunosuppressive effects. While IFN-γ is the most frequently studied MSC 
priming regimen, we believe that hypoxia is a relatively low cost addition that not only promotes 
glycolysis but also enhances the IFN-γ induced expression of IDO and HLA-G. Priming MSCs 
in this manner should lead to a more standardized and efficacious therapy, which could be 
explored for treatment of dozens of autoimmune and inflammatory disorders. 
 
3.5 Future Directions 
While our focus is on the development of MSCs as an immnuosuppressive cell therapy, recent 
attention has also been paid to the extracellular vesicles they secrete, specifically those with a 
size <100-150 nm called exosomes.101,102 Several studies have shown these exosomes have 
therapeutic benefit for applications such as ischemia-reperfusion injury,103,104 fracture healing,105 
and graft-vs-host-disease.106 
An interesting feature about the therapeutic ability of these exosomes is that it does not 
require priming. While unprimed MSCs become primed when they are injected into a patient 
with an inflammatory disorder, the exosome fraction of unprimed MSCs is collected before they 
	 38	
have a chance to respond to inflammation. This thesis has shown that unprimed MSCs have low 
expression of the immunosuppressive proteins implicated in their function as a cell therapy. 
Thus, the exosomes from unprimed MSCs must work by a separate mechanism. 
Nevertheless, it is possible that if priming MSCs leads to a better cell therapy, it may also 
improve the therapeutic potential of the exosomes they secrete. This led to us conducting some 
pilot studies to see if exosomes from control, IFN-γ, hypoxia, or dual primed MSCs would be 
more inhibitory in MLRs. Since our lab does not have an ultracentrifuge, the polymer method 
was used for exosome isolation.107 This takes advantage of the ability of polyethylene glycol 
(branded as ExoQuick TC) to pull large particles out of suspension. Unfortunately, after many 
experiments with some inconsistent data, we discovered that the polymer also isolated the IFN-γ 
protein. Hence, pro-inflammatory cytokine was being dosed into MLRs alongside exosomes 
(which are presumably immunosuppressive). Future attempts at studying the therapeutic 
potential of exosomes from IFN-γ primed MSCs should use a different method of exosome 















Aim 2: To conduct a global proteomic and metabolomic 
characterization of single vs. dual IFN-γ/hypoxia primed 
MSCs  
4.1 Overview  
Our previous studies demonstrated that hypoxia can enhance the immunomodulatory function of 
MSCs by altering cell metabolism. Given there have been many papers on hypoxia 
preconditioning of MSCs, it was somewhat surprising that this mechanism had not been 
previously described. However, if the paradigm has thus far been that “cytokines license MSCs 
to be anti-inflammatory” and “hypoxia affects cell survival and angiogenesis”, then it is easy to 
only look for these same patterns in new studies and applications. 
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Recognizing that in our own study we limited our analysis to the effects of priming on 
immune modulation, we challenged ourselves to acquire a more global understanding of how 
these environmental cues affect diverse aspects of MSC behavior. Certainly, the therapeutic 
capacity of MSCs would also be affected by changes to viability, migration capacity, and so 
forth. Our second aim was thus to uncover the changes to the proteome and metabolome of 
MSCs upon exposure to IFN-γ, hypoxia, or both cues together. While our findings should lend 
insight to how different priming regimens may (or may not) benefit MSCs for treatment of 
diverse clinical indications, they may also reflect the adaptations unprimed MSCs make upon 
administration to patients with hypoxic or inflammatory disorders.     
 
4.2 Methods	
4.2.1 Mass spectrometry  
Protein was collected from MSCs via a methanol-chloroform extraction protocol. MSC plates 
were washed x 3 with ice-cold PBS to thoroughly remove residual FBS and cytokines. 450 µL of 
lysis buffer consisting of TBS with 3% SDS and 50 µL protease inhibitors (Sigma # P8340) was 
applied to each MSC plate. The lysate was collected in a 1.5 mL tube and incubated at 60 °C for 
30 minutes. 400 µL of methanol and 100 µL of chloroform were added, and samples were 
vortexed and centrifuged at 16 000 x g for 1 min. The protein pellet was washed with methanol 
three times and allowed to air dry before final resuspension in 30 µL of solubilization buffer (100 
mM ammonium bicarbonate, 8 M urea, and 0.1 M DTT in Optima water) and snap freezing with 
liquid N2 for storage at -80 °C. Immediately prior to analysis, samples were further reduced, 
alkylated, and trypsin digested, and yeast alcohol dehydrogenase was added as an internal 
control. Samples were collected from biological triplicates, where each replicate of a given 
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priming condition came from a separately thawed cryovial of MSCs. Each individual sample was 
additionally run in duplicate. Mass spectrometry was performed at the Quantitative Proteomics 
and Metabolomics Center at Columbia University with an UltiMate 3000 RSLCNano 
ultrapressure liquid chromatograph coupled to a Q Exactive HF (Orbitrap) mass spectrometer 
(ThermoFisher). More detailed methods can be found in the supplemental information (SI). 
iPathway Guide (Advaita, 2017) and String v10.5 (string-db.org/) were used to 
understand the nature of the differentially expressed (DE) proteins, which were defined by a 
|log2 fold change (log2FC)| > 0.6 and a p  < 0.05. All proteins are listed by their related gene 
names, as these are the names used in the iPathway Guide program.  
 
4.2.2 Metabolomics analysis  
MSC plates (6-well) were washed three times with ice-cold PBS to thoroughly remove residual 
FBS and cytokines. 500 µL of chilled 80% methanol containing internal standard (17 µM 4-
chlorophenylacetic acid) were then added to each well, and the plates were placed on a shaker 
for 30 minutes in a cold room. Samples were subsequently collected into 15 mL Falcon tubes, 
with lysate from two full 6-well plates used for each individual sample. As with the proteomics 
set up, there were three biological replicates for each priming condition. Samples were stored at  
-80 °C before analysis at the Quantitative Proteomics and Metabolomics Center at Columbia 
University, where the metabolomics analysis was performed (detailed methods in SI). 
 
4.3 Results 
4.3.1 Overview of data 
MSCs used for proteomic and metabolomics analyses had a viability of >94%, based on trypan 
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blue exclusion, with no significant differences based on exposure to hypoxia or IFN-γ. While we 
did not observe a change in morphology indicative of undesired differentiation, exposure to IFN-
γ did increase the average cell diameter (Figure S2), as has been observed by others. Our prior 
studies have also shown minimal changes to MSC surface marker expression, with the exception 
that IFN-γ leads to expression of HLA-DR, which is not expressed at baseline.  
A total of 3,465 proteins were detected, with 2,435 proteins identified by >1 peptide 
(conservative set). Many proteins identified by only one peptide are accurate results; however, 
the conservative set will be presented in figures, and tables will indicate when including proteins 
outside of this set. Our own validation studies can be seen in Figure S3, which also serves to 
validate some of the smaller magnitude (yet significant) findings.  
Figure 13a shows the overlap in differential expression (DE) of proteins amongst 
priming conditions, with the 31 DE proteins from all priming conditions shown in Figure 13b. 
a b
Figure 13 Overview of data. a) The total number, and overlap amongst priming conditions, of proteins that 
show significant differential expression compared with control MSCs b) STRING network of the 31 proteins that 
are differentially expressed from all priming conditions. 
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The most central node is dihydropyrimidine dehydrogenase (DPYD), the rate-limiting-step in 
pyrimidine metabolism.  
Table 3 documents the percentage of the 2,435 proteins that are DE for each priming 
condition. IFN-γ priming led to a significant change in expression in ~12% of the proteins, 
hypoxia led to a change in ~9% while dual IFN-γ/hypoxia priming led to a change ~21%.  The 
very neat addition (9+12=21), suggests that IFN-γ and hypoxia alter distinct pathways without 
much overlap (only 41 proteins as per Figure 13a). In further support of this, most proteins with 
DE following hypoxia were mitochondrial, 
whereas IFN-γ predominantly affected non-
mitochondrial proteins.  
Metabolomics analysis identified forty-
seven intracellular metabolites with strong 
confidence. The relative abundances of nine metabolites are highlighted in Table 4. Priming 
with IFN-γ resulted in higher increases in b-alanine levels than priming with hypoxia, but both 
cues acted together to produce the 
highest amounts of this metabolite 
in dual-primed cells. Taurine and 
hypotaurine showed similar trends 
to b-alanine. While a relative 
abundance of 1E+99 implies there 
was no detectable metabolite in the 
control MSCs, the relative 
abundance of taurine in IFN-γ primed vs. hypoxia primed cells was 6.06-fold higher (evident 
Table 3 Overview of the impact of IFN-y and/or 
hypoxia on the MSC proteome. 
Table 4	Relative metabolite abundance in IFN-γ and hypoxia 










Beta-	alanine 6.56 1.63 10.60
hypotaurine	 2.27 1.51 3.45
L-kynurenine	 1E+99 0.00 1E+99
L-tyrosine		 1E+99 0.00 1E+99
D-glucose	 1.20 1.45 2.88
O-Phosphoethanolamine 1.15 2.92 2.45
pyruvic	acid	 0.72 0.44 0.49
L-(+)	lactic	acid	 0.55 1.54 1.83
taurine	 1E+99 1E+99 1E+99
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from larger data set). There was no significant difference in relative abundance of kynurenine or 
tyrosine in IFN-γ primed vs. dual primed cells. 
 Given the above changes in the expression of proteins and metabolites, we analyzed their 
relevance to four biological settings: metabolism, immune modulation, extracellular matrix 
(ECM), and cell survival. Of note, these are only tentative boundaries, as one pathway often has 
a direct influence over another.  
 
4.3.2 Effects on cellular metabolism 
Exposure to hypoxia resulted in significant changes in carbon metabolism. MSCs had broad 
upregulation of proteins involved in glycolysis and a greater capacity for uptake of glucose 
(GLUT1/SLC2A1) and fructose (GLUT5/SLC2A5), as well as for export of lactate 
(MCT4/SLC16A3) and hydrogen ions (CA12). By contrast, TCA cycle proteins were mostly 
downregulated, as were the enzymes involved in fat degradation and transport, amino acid 
catabolism and transport, and the electron transport chain (ETC). Consistent with the fewer 
mitochondrial proteins, mitochondrial ribosomal proteins (MRP family) were downregulated. 
Hypoxia also influenced glycogen turnover, as both glycogen synthase and glycogen 
phosphorylase L were upregulated. 
IFN-γ had a more selective impact on metabolism. While generally not altering any 
pathway at every step, IFN-γ led to an upregulation of GLUT5 (log2FC = 5.32 vs. only 1.55 
from hypoxia), cytoplasmic aconitase (ACO1/IRP1), hexokinase II (HKII), and long chain acyl-
CoA synthetase (ACSL5). Curiously, these proteins were also upregulated by hypoxia (Figure 




Figure 14 The effect of dual IFN-γ/hypoxia priming a) on glycolysis, b) neutral amino acid degradation c) the 
TCA cycle d) fat degradation and e) the electron transport chain. Note that the trends are similar for hypoxia primed 
cells, however, co-exposure to IFN-γ reinforced the upregulation of HKII, ACO1, and ACSL5, which are indicated 
with a black star («) in panels A, C, and D, respectively. Beyond upregulating these proteins, IFN-γ had an 












closer to the metabolic changes observed with hypoxia, but with an even greater induction of the 
four proteins mentioned. These trends can be seen in Figure 14a-e, which demonstrates the 
combined changes in metabolism for dual primed MSCs. Only dual primed cells significantly 
upregulated proteins involved in gluconeogenesis (Figure S4). 		
4.3.3 Effects on immune modulation 
The immune regulatory function of 
MSCs is thought to be one of their 
most important qualities and highly 
responsive to microenvironmental 
cues. Curiosly, hypoxia did not lead 
to DE of proteins implicated in 
traditional immune pathways. By 
contrast, IFN-γ had a large impact. 
For example, IFN-γ induced 
expression of proteins associated 
with antigen presentation (Figure 
S5), the defense against viral and 
microbial pathogens (IFIT, TRIM, 
NOD, and CXCL families; Supp. File 1), and chemotaxis (CXCL9-CXCL11, CD47, CD97). 
 IFN-γ exposure also resulted in upregulation of factors that promote the complement 
cascade (C1QBP, C1R, C1S). While these factors could put MSCs at greater risk for 
IFN-γ Hypoxia Dual Function
C1QBP -0.12 -1.2 -1.13 inhibits	complement	factor	1
C1R 2.55 -0.51 2.66 forms	complement	factor	1
C1S 2.01 -0.07 1.94 forms	complement	factor	1
CD47 1.24 0.01 1.19 protection	from	phagocytosis;	
transendothelial	migration
CD97 1.39 0.17 1.23 chemotaxis
CFH 6.8 0.49 7.38 helps	direct	complement	to	
pathogens	vs.	host	cells
CSF1 3.41 -0.28 3.18 monocyte	maturation
CXCL9 6.51 0.03 6.8 chemotaxis;	antimicrobial
CXCL10 2.04 0.12 1.96 chemotaxis;	antimicrobial
CXCL11 2.44 -0.13 2.38 chemotaxis;	antimicrobial
HLA-E 3.01 -0.03 3.47 protects	cells	from	NK	cells
HLA-F 7.16 0.16 6.97 possibly	immune	tolerance
IDO1 6.64 0.19 6.51 immune	tolerance
LGALS3BP 1.54 -0.22 1.32 galectin	3	binding	protein
LGALS9B 4.76 -0.88 4.11 analog	of	galectin	9
LRRC32 0.3 0.35 0.89 promotes	surface	expression	
of	TGF-β	on	T-regs
SERPING1 3.61 0.81 3.7 inhibits	complement	factor	1
PDL1 6.38 -0.2 6.27 immune	tolerance








Table 5 Differential expression (log2 FC relative to control 
MSCs) of proteins related to the complement cascade, immune 
tolerance, and leukocyte migration. * identified by only 1 peptide. 
	 47	
complement-related cell death and clearance, it is notable that SERPING1 and complement 
factor H (CFH) were highly induced (Table 5), which could provide protection.  
Other factors that could protect MSCs from immune mediated clearance were 
upregulated, such as CD47, HLA-E, PD-L1, as well as the 
tryptophan catabolizing enzyme indoleamine-2,3-
dioxygenase (IDO1). TGF-b1 had the highest induction in 
dual primed cells but at a low level (log2FC = 0.58). 
However, a related protein, LRRC32, was significantly 
induced in dual primed cells. Several proteins associated 
with MSC immune modulation by others - HLA-G, HGF, 
LIF, NOS2/iNOS, and TSG-6 - were not detected in any 
MSC groups.98  
 
4.3.4 Effects on extracellular matrix  
Both IFN-γ and hypoxia had large impact on the ECM 
(Table 6). IFN-γ predominantly affected the production of 
collagen components, with significant downregulation of 
collagens 1-3, 5, 12, 15 and 16, and upregulation of 
collagen 4. IFN-γ also increased laminin alpha chains and 
agrin, while downregulating elastin and fibulin. Hypoxia 
upregulated collagen 6 and had many effects similar to 
IFN-γ. Consequently, the DE patterns of dual primed cells 
were often suggestive of synergistic influences of the two 
Table 6 Differential expression (relative 
to control MSCs) of proteins related to 
the ECM. log2 FC is shown. *proteins 
identified by only 1 peptide. 
IFN-γ	 Hypoxia Dual
AGRN 4.35 1.47 6.16
COL1A1 -1.37 -0.57 -2.22
COL1A2 -1.03 -0.48 -1.61
COL2A1 -1.42 -0.64 -2.67
COL3A1 -1.05 0.13 -1.16
COL4A1 0.65 0.46 1.21
COL4A2 0.51 0.54 4.18
COL5A1 -0.75 -0.14 -0.92
COL5A2 -0.9 -0.74 -2.27
COL6A2 0.18 0.61 0.89
COL6A3 0.1 0.63 0.76
COL12A1 -0.97 -0.96 -2.59
COL15A1 -1.06 -0.56 -1.77
COL16A1 -0.71 -0.2 -0.67
ELN -1.27 -0.26 -1.36
FBLN1 -0.73 -0.45 -0.17
FBN1 -0.02 0.26 0.91
LAMA2 0.67 -0.15 1.34
LAMA4 1.67 0.27 1.83
LAMB1 -1.03 -0.37 -1.11
LAMC1 -0.67 0.05 -0.38
LOX -0.43 1.05 0.96
LOXL1 0.22 0.72 2.11
LOXL2 -0.79 0.99 0.27
LOXL3 0.65 2.72 4.21
PLOD1 0.08 0.68 0.49
PLOD2 0.27 1.74 1.9
SPARC -1.56 0.21 -1.13
THBS1 -1.25 0.13 -0.76
THBS2 -1.62 0.16 -1.04
TIMP1 0.38 0.91 0.89
TIMP3 -0.56 0.37 -0.86






cues, with the most dramatic example being COL4A2, where IFN-γ or hypoxia conditioning 
resulted in log2FC = 0.5, while dual priming resulted in log2FC = 4.18.  
 These cues also affected regulators of ECM metabolism and angiogenesis. Hypoxia had a 
large effect on collagen crosslinking, as it upregulated several lysyl oxidases (LOX, LOXL1-3) 
and lysyl hydroxylases (PLOD1&2). When MSCs were dual primed, induction of LOXL1 and 
LOXL3 was bolstered even further, suggesting another area of synergy. Dual priming also 
affected expression of TIMP1 and TIMP3, which were upregulated and downregulated, 
respectively, and led to unique induction of tenascin-C. Lastly, IFN-γ and dual primed cells 
downregulated thrombospondins 1&2, which act to inhibit angiogenesis.  
 
4.3.5 Effects on cell survival  
When cultured in monolayers at basal culture conditions, MSCs experience cues that maintain 
cell survival. Once injected into patients, however, the MSCs lose their attachment sites and 
experience stressful signals such as hypoxia and inflammation. We therefore investigated how 
these cues affect the pathways directly related to cell survival: anoikis, apoptosis, and autophagy.   
 
Several anoikis-resistance factors were upregulated following hypoxia and IFN-γ exposure 
(Figure 15). S100A4 was upregulated by both IFN-γ and hypoxia (log2FC = 0.75 and 0.64, 
respectively), while the greatest induction came from dual priming (log2FC =1.59). Dual primed 
cells also showed the greatest upregulation of ANGPTL4 (log2FC = 2.56 vs. 2.05 from hypoxia 
alone), induction of both PDGFRA and PDGFRB, and unique upregulation of integrin alpha 
chain V (ITGA5). 
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Figure 15 Interrelation of anoikis, apoptosis, and autophagy. * proteins that were identified by a single peptide. 
Bold type indicates significant effects of dual priming when compared to single priming. Proteins listed for 
apoptosis and autophagy were identified using pathways on iPathway Guide, and those related to survival from 
anoikis were determined from literature.108–112  
 
The changes to apoptosis-related genes were suggestive of both promotion and inhibition 
of this process. The promotion of apoptosis was evidenced by the increases in expression of 
cathepsins, caspase 7 and NFKBIA, and decreases in expression of BCL2L1 and PDPK1. The 
inhibition of apoptosis was evidenced by increased expression of MAP2K1, RAF1 and RELA, 
and decreased expression of AIFM1, CYCS, DIABLO, SESN2, and TNFR10B & D (TRAIL 
3.5. Effects on cell survival
When cultured in monolayers at basal cuture conditions, MSCs
experience cues that maintain cell survival. Once injected into pa-
tients, however, the MSCs lose their attachment sites and experi-
ence stressful signals such as hypoxia and inflammation. We
therefore investigated how these cues affect the pathways directly
related to cell survival: anoikis, apoptosis, and autophagy.
Several anoikis-resistance factors were upregulated following
hypoxia and IFN-g exposure (Fig. 3). S100A4 was upregulated by
both IFN-g and hypoxia (log2FC¼ 0.75 and 0.64, respectively),
while the greatest induction came from dual priming
(log2FC¼ 1.59). Dual primed cells also showed the greatest upre-
gulation of ANGPTL4 (log2FC¼ 2.56 vs. 2.05 from hypoxia alone),
induction of both PDGFRA and PDGFRB, and unique upregulation of
integrin alpha chain V (ITGA5).
The changes to apoptosis-related genes were suggestive of both
promotion and inhibition of this process. The promotion of
apoptosis was evidenced by the increases in expression of ca-
thepsins, caspase 7 and NFKBIA, and decreases in expression of
BCL2L1 and PDPK1. The inhibition of apoptosis was evidenced by
increased expression of MAP2K1, RAF1 and RELA, and decreased
expression of AIFM1, CYCS, DIABLO, SESN2, and TNFR10B & D
(TRAIL receptors). Other proteins listed in Fig. 3 have variable,
context-specific effects. Overall, IFN-g and hypoxia seemed to have
mixed effects on apoptosis, which was also seenwith dual priming.
All proteins listed under autophagy served to facilitate that
pathway (Fig. 3). As with apoptosis, there were changes that both
promote and inhibit this process. IFN-g upregulated TRIM21 and
TRIM22, whereas hypoxia highly induced BNIP3 (log2FC¼ 3.47),
and both factors induced HKII. BNIP3 and HKII had an even greater
induction from dual priming, while SESN2 was synergistically
downregulated (the most downregulated protein in the whole data
set). Since SESN2 is also pro-apoptotic, its downregulation may
have consequences for both autophagy and apoptosis.
Beyond the pathways listed above, some additional metab-
olomics changes described in Table 2 are worth highlighting. For
example, taurine has many anti-oxidant and cytoprotective prop-
erties [25e27], and this metabolitewas found in all primed cells but
was undetected in control MSCs. b-alanine was also upregulated in
all priming conditions. This amino acid is the precursor to the anti-
oxidant carnosine, which has shown cytoprotective properties in
similar situations to taurine [28,29]. b-alanine is made from py-
rimidine metabolism, and its accumulation in primed cells is
Fig. 3. Effect of IFN-g and/or hypoxia on the interrelated survival pathways of anoikis, apoptosis, and autophagy. * proteins that were identified by a single peptide. Bold type
indicates significant effects of dual priming when compared to single priming. Proteins listed for apoptosis and autophagy were identifi using pathways on iPathway Guide, and
those related to survival from anoikis were determined from literature. [20e24].
H.M. Wobma et al. / Biomaterials 167 (2018) 226e234 231
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receptors). Other proteins listed in Figure 15 have variable, context-specific effects. Overall, 
IFN-γ and hypoxia seemed to have mixed effects on apoptosis, which was also seen with dual 
priming.  
 All proteins listed under autophagy serve to facilitate that pathway (Figure 15). As with 
apoptosis, there were changes that both promote and inhibit this process. IFN-γ upregulated 
TRIM21 and TRIM22, whereas hypoxia highly induced BNIP3 (log2FC = 3.47), and both 
factors induced HKII. BNIP3 and HKII had an even greater induction from dual priming, while 
SESN2 was synergistically downregulated (the most downregulated protein in the whole data 
set). Since SESN2 is also pro-apoptotic, its downregulation may have consequences for both 
autophagy and apoptosis. 
 Beyond the pathways listed above, some additional metabolomics changes described in 
Table 4 are worth highlighting. For example, taurine has many anti-oxidant and cytoprotective 
properties,113–115 and this metabolite was found in all primed cells but was undetected in control 
MSCs. b-alanine was also upregulated in all priming conditions. This amino acid is the precursor 
to the anti-oxidant carnosine, which has shown cytoprotective properties in similar situations to 
taurine.116,117 From a biological standpoint, b-alanine is made from pyrimidine metabolism, and 
its accumulation in primed cells is consistent with their upregulation of DPYD – the first enzyme 
in this pathway.  
 
4.4 Discussion 
Several meritorious studies have been dedicated to identifying the protein expression profile of 
MSCs derived from different tissue sources.118,119 Regardless of tissue source, when MSCs are 
kept in basic culture conditions, their baseline behavior does not represent the many adaptations 
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they make in the setting of injury and disease. Since inflammation and hypoxia are common to 
many pathological environments, we sought to better understand the biology of therapeutic 
MSCs via simulating these signals with 1% O2 and IFN-γ. Our goal was to get insight into the 
proteomic and metabolomic changes of MSCs co-exposed to these cues for 48h, and to parse out 
the relative contribution of each factor and identify synergies. The major themes we uncovered 
are that IFN-γ induces MSCs to contain an injury by limiting damage from infection, 
inflammation and fibrosis, while hypoxia promotes adaptation to low oxygen via increasing 
proteins involved in anaerobic metabolism, angiogenesis, autophagy, and cell migration. 
Combining these cues roughly combines their individual effects, with additional synergies. 
As expected, IFN-γ had a strong impact on MSC immune modulation. Our study 
confirmed some well-known downstream effects of interferons, such as upregulation of HLA 
proteins, anti-microbial and anti-viral factors, and the immunosuppressive proteins IDO and PD-
L1.23 However, we also uncovered some less described proteins and metabolites that could 
confer MSC protection. For example, IDO is known to inhibit T-cells via metabolizing 
tryptophan to kynurenine (supported by our metabolomics data). This tryptophan depletion could 
also be harmful to MSCs. Thus, it is interesting that IFN-γ upregulates tryptophanyl tRNA-
synthetase (a.k.a. WARS), which could serve as a MSC-protective method by replenishing 
intracellular tryptophan stores.120  
IFN-γ also led to a mild induction of CD47, which binds to the SIRPa receptor on 
macrophages and has been described as a “don’t eat me” signal (blocks phagocytosis) that may 
also promote peripheral tolerance.121 This pathway has been implicated as a mechanism for 
tumor immune escape, and could be an interesting lead to pursue for MSC 
immunomodulation.122  We also noted strong induction of the complement inhibitory factor – 
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CFH. MSCs, particularly the cryopreserved products used in industry-sponsored clinical trials, 
have been shown to activate the complement cascade, expediting MSC lysis and clearance.123 
Since the therapeutic utility of MSCs would presumably be better if they had a longer half-life, 
one group coated the cell surface with CFH to prevent this type of clearance.124 Our data indicate 
a similar effect may result from simply exposing MSCs to IFN-γ. Lastly, we observed induction 
of the cell-protective metabolites, taurine and b-alanine, the latter of which is protective upon 
conversion to carnosine.114–117 
 Beyond immune modulation, IFN-γ produces an anti-fibrotic MSC phenotype. Except for 
collagen IV and agrin, IFN-γ downregulates all other structural ECM proteins. Agrin is an ECM 
proteoglycan part of the basement membrane, so its upregulation with collagen IV is consistent 
with preserving basement membrane formation. However, agrin has also been implicated as part 
of the immune synapse, and so its upregulation may be related to that function.125 The otherwise 
widespread decrease in structural proteins is significant, because tissue fibrosis from excessive 
deposition of ECM is a common consequence of unchecked inflammation and is detrimental to 
having functional tissues.126 Thus, IFN-γ priming of MSCs may help prevent pathological 
fibrosis by both inhibiting inflammation and decreasing ECM secretion. This anti-fibrotic effect 
has clinical relevance. In one study, patients treated with recombinant IFN-γ significantly 
reduced the development of liver fibrosis in the setting of chronic hepatitis B.127 
 While IFN-γ instructs MSCs to resolve tissue injury, hypoxia leads to many survival 
adaptations. First, hypoxia shifts cell metabolism towards non-oxygen dependent strategies – 
namely glycolysis and glycogenolysis. To facilitate the reliance on these pathways, cells increase 
lactate dehydrogenase, lactate transporters, glucose and fructose transporters, and carbonic 
anhydrase (to assist with pH balance)128. Degradation and transport of amino acids and fatty 
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acids, which generally feed into the TCA cycle and ETC (oxygen dependent), are 
downregulated, as is mitochondrial protein expression in general.  
 A second approach to survival is through conservation of energy stores via autophagy. 
We observed significant induction of the pro-autophagic BNIP3, which is consistent with studies 
by others.110  Lastly, MSCs can attempt to restore a physoxic environment by promoting 
angiogenesis or migrating away from the low oxygen region. Consistent with reports by others, 
we found that hypoxia upregulates the entire family of lysyl oxidase (LOX, LOXL1-3) and lysyl 
hydroxylase (PLOD1&2) enzymes, which serve to cross-link collagen and elastin. These 
proteins are associated with promoting angiogenesis129 and cell migration.130,131 The additional 
upregulation of anoikis-resistance proteins like ANGPTL4 and S100A4, may facilitate survival 
during this process.10,109,110  
The collective adaptations to hypoxia may inadvertently make MSCs a better cell 
therapy. Several animal studies have shown that hypoxic preconditioning of MSCs before 
administration enables them to better survive in the clinical setting of ischemia. Upregulation of 
autophagy has been directly shown to contribute. In one study, preconditioning MSCs with 
hypoxia improved their ability to repair infarcted hearts; however, this difference was partially 
abolished by an autophagy inhibitor. The changes in metabolism could also influence the 
immune modulatory function of MSCs. As has been described in the tumor literature, when cells 
(like MSCs) prioritize glycolysis for their own survival, they inhibit inflammatory immune cells 
in the nearby environment through glucose competition and lactate signaling.132–134 This would 
explain why hypoxia preconditioned cells have a better ability to suppress T-cells in vitro 
without superior upregulation of immunosuppressive proteins like IDO.73  
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Clearly the response of MSC to IFN-γ and hypoxia are very different, and it makes sense 
that combining these cues results in additive effects. Indeed, dual primed cells demonstrate the 
metabolic changes of hypoxia, the immunomodulatory changes of IFN-γ, and the ECM and 
survival changes of both cues. Nevertheless, there were many points of synergy.  
While hypoxia alone did not upregulate any immunosuppressive factors, dual IFN-
γ/hypoxia exposure led to synergistic upregulation of LRRC32 (a.k.a. GARP), which is known to 
tether TGF-b1 (also most abundant in dual primed cells) to regulatory T-cells and 
megakaryocytes and play a role in the immunosuppressive function of MSCs.135,136 Dual priming 
also downregulates structural ECM proteins and upregulates basement membrane proteins 
beyond IFN-γ alone, and upregulates LOXL enzymes more than hypoxia alone. The LOXL 
family has been shown to cross-link ECM proteins to attract anti-inflammatory macrophages, 
promote angiogenesis, and mobilize cells to migrate to distal organs.130,131,137,138 Survival in this 
“metastatis-like” scenario is consistent with dual primed cells having the highest expression of 
ACSL5, ANGPTL4, BNIP3, HKII, PDGFRA, S100A4, as well as taurine and b-alanine 
(precursor to carnosine). 
While we have attempted to profile how MSCs respond to a diseased microenvironment, 
several limitations should be considered. Clearly, more than hypoxia and IFN-γ are present in 
vivo, as there are many other paracrine factors and immune cells that will affect MSC behavior. 
Our analysis is meant to isolate the effect of at least two of these factors to help us understand 
how they contribute to the whole. In doing so, we also gain insight towards the many ways by 
which priming MSCs with these cues beforehand could enhance their therapeutic capacity 
(immune modulation, pro-survival etc.).70,139  
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A second limitation is that the samples comprised of adherent cells that were healthy 
from ~10 days in cell culture. MSCs used in industry sponsored clinical trials are cryopreserved, 
thawed, and injected within a few hours. Loss of attachment can be expected to affect cell 
viability, and cryopreservation is known to affect MSC metabolism, viability, and responsiveness 
to IFN-γ.140–142  Our data thus represent the best-case-scenario, as the proteome and metabolome 
of recently thawed cells may be less malleable.  
Finally, there are three outstanding questions: 1) What is the role of ACO1/IRP1 
upregulation from IFN-γ and hypoxia? 2) What is the function of GLUT5 upregulation when 
blood fructose levels are low? Given that IFN-γ upregulates ASCL5 and SLC27A3, does IFN-γ 
have a meaningful effect on long chain lipid metabolism?  
 
4.5 Future Directions 
The mass spectrometry and metabolomics findings revealed many interesting changes, which 
have yet to be fully characterized. For example, two potentially self-protective proteins 
upregulated by IFN-γ were CD47 and CFH, and it would be interesting to explore how clinically 
relevant these proteins are (or could be, if further overexpressed) in terms of facilitating MSC 
survival and function in vivo. Hypoxia also had a profound impact on ECM modification, which 
has been described in the cancer literature, but the functional relevance to clinical MSC therapies 
has yet to be explored. Further studies could help discern if these ECM changes make the MSCs 







Chapter 5  
 
 
Aim 3: To compare the ability of dual IFN-γ/hypoxia primed 
vs. unprimed MSCs to prevent disease progression in models 
of acute GvHD 
5.1 Overview  
Since the mid-2000s, there have been hundreds of clinical trials registered for assessing the 
utility of MSCs in treating immune disorders. One of the most well-studied indications has been 
acute GvHD.143–146 GvHD is a common complication of foreign donor hematopoietic stem cell 
transplantation (allo-HCT; a.k.a. bone marrow transplant), whereby immune cells in the graft 
attack the patients’ tissues, particularly the skin, gastrointestinal tract, and liver, which can lead 
to organ failure and death. Steroids are the first line treatment but only provide a complete 
response in 25-40% of patients.145 Second-line treatments do not fare much better and increase 
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the risk of deadly opportunistic infection. The failure of multiple immunosuppressive drugs to 
provide a safe and effective therapy suggests a new category of therapy is warranted. 
 MSCs have been evaluated in many case reports and clinical trials for acute GvHD145,147. 
Unlike other immunosuppressive drugs, few side effects have been described, conferring a clear 
safety benefit. However, the efficacy of these MSCs has been unconvincing. While they have 
shown promise in case reports and in Phase II clinical trials, a Phase III trial testing a commercial 
MSC product (Prochymal) failed to meet its primary endpoint,52 and MSC therapies have yet to 
gain FDA approval. 
 Based on the functional and proteomic characterization of dual IFN-γ/hypoxia primed 
MSCs, we believe they may be better able to prevent the progression of GvHD than their 
unprimed counterparts. To test this, we evaluated them in a commonly used xenogeneic mouse 
model of GvHD.148 This model has the advantage of pairing human immune cells (the disease-
causing HCT) with human MSCs (the therapeutic cells), although it is still a partially xenogeneic 
model, since the human immune cells attack mouse tissues.  
Given that animal studies do not always predict clinical efficacy, we also sought to 
leverage our lab’s experience in engineering human tissue models of disease from stem 
cells.149,150 There are no published reports of a tissue engineered GvHD model; however, a study 
from 1988 describes an ex vivo system of skin GvHD whereby immune cells from the HCT 
donor are initially co-cultured with APCs from the putative patient and are then added to a 
biopsy punch of the patient’s skin.151 The severity of skin GvHD that developed (histological 
grade) in this model was predictive of the severity that developed after the patient underwent 
HCT. To have more control over system components, we have been re-creating this model but 
with tissue engineered skin. Our progress is ongoing, but we anticipate this could be a 
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complementary model to mouse studies for testing potential new GvHD therapeutics.  
 
5.2 Methods 
5.2.1 Induction of GvHD in a xenogeneic mouse model  
NOD.Cg-PrkdcscidIl2rgtm1Wjl/SzJ (NOD-scid IL2rγnull abbreviated as NSG) mice were purchased 
from Jackson Laboratories, (Bar Harbor, ME). Mice were used in experiments at 8-12 weeks of 
age and housed in a specific pathogen-free microisolator environment. All protocols were 
approved by the Columbia University Institutional Animal Care and Use Committee (IACUC). 
NSG mice were conditioned with sublethal total-body irradiation (TBI; RS 2000 X-ray 
Irradiator, Rad Source Technologies, Inc. (Buford, GA, USA)) followed by next-day intravenous 
injection of fresh PBMCs into the mouse tail vein. Mouse survival was checked every day, and 
body weight was measured every 3-4 days.  
 
5.2.2 Administration of therapeutic MSCs to mice  
Control (unprimed) human MSCs or dual IFN-γ/hypoxia primed MSCs (0.75 x 106) were 
intravenously injected into the mouse tail vein on the same day as human PBMCs. Prior to 
injection, the MSCs were washed x3 in PBS to eliminate FBS and cytokines, and were 
resuspended in BMM for delivery. To prevent mouse death from MSC emboli to the pulmonary 
vasculature, cells were filtered through a 30 µm mesh immediately before delivery, reducing 
MSCs to single-cell suspension. They were also injected in a total volume of 500 µL, via two 
slow pushes of 250 µL. This led to a >95% immediate survival rate.  While all MSC lines were 
tested negative for mycoplasma and looked sterile prior to injection, mice were still provided 
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with medicated water that contained trimethoprim and sulfamethoxazole (Hi-Tech Pharmacal. 
Co. Inc., (Amityville, NY)). 
 
5.2.3 Engineering an immunocompetent full skin equivalent (FSE) to model GvHD 
To emulate the 1988 explant model of skin GvHD but using tissue engineered skin, it was 
necessary to develop a method for acquiring blood cells that were autologous to pluripotent stem 
cells. Our collaborators in the Christiano lab have experience with engineering full skin 
equivalents (FSE) from induced-pluripotent stem cells (iPSC).152 However, when these cell lines 
are purchased from commercial vendors or acquired by material transfer agreements from other 
universities, it is impossible to acquire blood cells that are autologous to the iPSC line. An 
obvious solution would be to try to differentiate the iPSC line to different blood cell lineages. 
While this has been done to a certain extent for macrophages,153 it is more challenging for other 
lineages (e.g. T-cells that need clonal diversity, APC subsets), and thus it would be easier to 
simply use matched blood samples. We thus co-developed an IRB protocol with the Center for 
Advanced Laboratory Medicine (CALM) that enables repeat blood collections from local, 
anonymous donors, where the first donation is also used to generate an iPSC line. Since the 
donors can be called back for future donations, there is a consistent source of blood cells, which 
have a normal biologic ratio amongst subsets, and they can be used fresh or cryopreserved for 
future use. The general concept is schematized in Figure 16.  
 
5.2.4 Generation and characterization of iPSC lines  
Blood-derived iPSC lines were generated in line with the CUMC institutional ethics review 
board. Small (8 mL) blood samples were collected by the CALM and immediately brought to the 
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Columbia Stem Cell Core for reprogramming of T-cells into iPSCs using the Sendai virus 
method.154	 Blood donations came from healthy individuals with the provision that future, larger 
donations could be arranged for having autologous immune cells to iPSC-derived tissues. The 
line “BS1” was used for all subsequent experiments.	
 Colonies of iPSCs were picked and cryopreserved, and expanded cells were evaluated by 
numerous means. These included flow cytometry for the pluripotency markers: Oct4, Nanog, 
Tra-1-60, and SSEA4 (performed by Columbia Stem Cell Core), karyotype analysis (outsourced 
to Cell Line Genetics), and tri-lineage differentiation (performed at Columbia Stem Cell Core 
using the R&D Human Pluripotent Stem Cell Functional Identification Kit). Cells were also 
tested for their differentiation potential to cardiomyocytes to evaluate how well standard 
























Figure 16 Schematic of our approach to producing fully autologous, immune competent tissues, such as full skin 
equivalents (FSEs) containing autologous dendritic cells (DCs). 
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5.2.5 Engineering FSEs using iPSC-derived keratinocytes and fibroblasts 
Fibroblasts were made from iPSCs as previously published by the Christiano lab, but with the 
new BS1 blood-derived iPSC line.155 Briefly, iPSCs were aggregated into embryoid bodies in 
iPSC media (-FGF, +0.3 mM ascorbic acid (Sigma), 10 ng/mL TGFβ2 (R&D), +ITS-A 
supplement) on low attachment plates. These were moved to gelatin-coated plates to induce cell 
outgrowth and switched to high glucose DMEM (+ascorbic acid, +20% FBS) for 10 days. Cells 
that demonstrated outgrowth were repeatedly passaged to obtain spindle-shaped cells. 
Keratinocyte (KC) differentiation was performed by modifications of the protocol 
described by Itoh et al. To make 3-D skin equivalents, type I collagen containing iPSC-derived 
fibroblasts was polymerized onto polyethylene terephthalate membranes for 5-7 days, as 
previously published.155 iPSC-KCs were then seeded onto the matrix and incubated for 6 days, 
after which the whole FSE was moved to the air-liquid interface to induce cornification of the 
epidermis for 7 days. 
 
5.2.6 Creating autologous dendritic cells 
The BS1 donor was asked to donate blood on several occasions. This was collected in CPT tubes 
(Becton Dickinson), which have a Ficoll layer imbedded such that spinning the tubes 
automatically separates out the PBMC layer. Some PBMCs were collected and cryopreserved as 
a source of autologous PBMCs for future studies. However, when dendritic cells were required, 
fresh BS1 PBMCs were magnetically sorted using CD14+ positive selection beads (Miltenyi) to 
first obtain the monocytes, which were differentiated to dendritic cells (DCs) using 50 ng/mL 
GM-CSF and 100 ng/mL IL-4 (Peprotech) for 5 days. Immature DCs were characterized by flow 
cytometry, using previously described methods and antibodies shown in Table S7. 
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5.2.7 Simulation of the GvH response 
To simulate the GvH response, BS1 DCs were co-cultured with either autologous or allogeneic 
PBMCs, as with previous MLR experiments. After 3 days of co-culture, some PBMCs were 
collected, seeded onto a collagen gel, and left overnight. Skin constructs were then transferred on 
top of the PBMC-containing gel (PBMC adjacent to dermis), and after four days of culture, the 
engineered skin was fixed and analyzed by H&E staining (JungU Shin). Other PBMCs in co-
culture with auto- or allogeneic DCs were left to react for 6 days to assess the T-cell division via 




5.3.1 Optimizing GvHD disease induction 
Initially, several different GvHD induction regimens were evaluated, which are shown in Figure 
17. Combining the highest cell and radiation dose (107 PBMCs, 1.5 Gy TBI) led to rapid disease 
progression. While mice in other groups maintained body weight until ~Day 15 post-transplant, 
mice that received the more aggressive regimen had all died by then. Indeed, the rate of mouse 
death was twice as rapid in this group compared with those that received a cell or radiation dose 
that was 25-33% lower. This aggressive induction regimen was chosen for future studies. 
	
Figure 17 Titration of different GvHD induction regimens. (a) Weight loss over time from 3 different induction 
regimens (b) Mouse survival over time from 3 different induction regimens. 
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5.3.2 Inhibition of xeno-GVHD via primed MSCs (pMSCs) 
In the next study, control (unprimed) or dual primed MSCs (pMSCs) were administered on Day 
0 along with the PBMCs. Mice in all groups showed a small initial drop in body weight due to 
the radiation; however, all groups were able to recover from this before the GvHD set in. While 
the same aggressive induction regimen was used as the dose-titration experiment (Figure 17), 
untreated mice in this study did not start to die until Day 12 (Figure 18b).  
The body weight and survival curves for the mice treated with control MSCs were not 
significantly different from the completely untreated group. Dual primed MSCs, by contrast, 
showed a relatively prolonged course for loss of body weight (Figure 18a), and survived 
significantly longer than untreated mice (Figure 18b). 
	
Figure 18 Effect of Control vs. Dual Primed MSCs on GvHD progression. (a) Weight loss over time. (b) Mouse 
survival over time. n = 8-13 per group. 
 
5.3.3 Blood-derived iPSC lines demonstrate pluripotency  
In parallel to in vivo studies, steps were taken towards developing an ex vivo, tissue-engineered 
skin GvHD model. The first step of this was to derive a blood-derived iPSC line, which was 
called BS1. This line was demonstrated to have differentiation capacity into endoderm, 
mesoderm, and ectoderm when induced with germline specific cues (Figure 19a).  
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Furthermore, the majority of these cells stained positive for the pluripotency markers Nanog, 
Oct4, and SSEA-4. Karyotype analysis of cells at a low passage number (<20) demonstrated no 
chromosomal abnormalities (Figure 19b).  
 
5.3.4 Extended differentiation of iPSCs leads to cells phenotypically similar to primary human 
KCs 
Extending KC differentiation protocols to 60 days led to a marked change in expression of key 
ECM proteins (Figure 20). Primary human KC have a very distinct bimodal expression pattern 
of Keratin-14 on flow cytometry analysis. iPSC differentiation protocols for 12 and 30 days 
looked identical to each other with a single Keratin-14 peak that was dimmer than that of 
primary cells. However, extending the differentiation to 60 days led to a bright, bimodal 
expression pattern identical to that of the primary human KCs. 	
Figure 19 (a) Demonstration of BS1 iPSC line pluripotency by germline differentiation and flow cytometry. (b) 
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5.3.5 Monocyte-derived DCs express expected DC markers  
Monocytes directed towards an immature DC phenotype were assessed by flow cytometry 
(Figure 21). As expected, DCs minimally expressed CD14 but highly expressed CD11c. Dermal 
DC markers (CD36 and DC-SIGN) were more highly expressed than epidermal DC markers 
(Langerin and E-cadherin). HLA-DR exhibited moderate signal, whereas CD80 was not 
expressed.  
		
Figure 21 Evaluation of monocyte-derived DC surface marker expression by flow cytometry. 










































































































Figure 20 Optimizing iPSCàKC 
differntiation. iPSCs were exposed to 
different durations of differentiation and 
then stained for the maturation marker 
Keratin-14  
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5.3.6 T-cells co-cultured with allogeneic DCs show greater activation and migration into FSE 
than those co-cultured with autologous DCs 
Violet-labelled PBMCs were co-cultured with DCs that were either autologous or allogeneic. 
After 6-days of co-culture, some cells were analyzed by flow cytometry (Figure 22). This 
revealed a small amount of T-cell division in the autologous case (14.9% of cells divided); 




Figure 22 Mixed lymphocyte reaction using autologous (left) vs. allogeneic (right) using DCs as stimulators and 
either autologous or allogeneic PBMCs as responders. Flow cytometry conducted after 6-days of co-culture. 




































































Some PBMCs were instead transferred to FSEs after only 3 days of co-culture with DCs 
(Figure 23). While PBMCs did not penetrate the dermis when they came from the autologous 








The severity of GvHD that develops is sensitive to many factors, including the PBMC dose, the 
radiation dose, as well as less controllable variables such as the microbiome a mouse adopts 
within a given barrier facility.156 We initially tested different doses of PBMCs and TBI to 
determine which induction regimen we should continue with for our MSC studies.  
The definition for a complete response in clinical trials that have used MSCs in steroid-
refractory GvHD patients has been “disease free survival by 28 days”. This might suggest that 
the two lower dose induction regimens we tested would be more appropriate, since they have a 
1-month disease progression. However, there are two factors to keep in mind. The first is that we 
are evaluating our MSCs as a preventative strategy and not in mice that already have late-stage, 
steroid-refractory disease. The second is that the human clinical trials dosed the MSCs twice a 
DCs	+	Autologous	T-cells DCs	+	Allogeneic	T-cells
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week for every week in that month, whereas we are only doing a single injection at the 
beginning.140 Multiple injections in a mouse model would increase the loss of mice from MSC 
pulmonary emboli. Thus, we decided to use the aggressive GvHD model, as that would 
maximize the ratio of time MSCs from our single injection would be in contact with the GvHD 
inducing immune cells. 
Having decided upon this aggressive induction regimen, we assessed the ability of a low 
dose (750,000 MSCs) of control vs. dual primed MSCs to slow disease progression. Dual primed 
cells clearly provided benefit over untreated mice based on the weight loss and survival curves, 
while control MSCs did not. Mice that received dual primed MSCs also had slower disease 
progression than those that received control MSCs; however, one mouse in the control MSC 
group survived to day 22, which was anomalous (all others had died by day 17) and prevented 
there being a statistically significant difference between these two experimental groups based on 
survival. Nevertheless, the data are encouraging.  
While we initially chose a relatively low dose of cells to prevent “over-dosing the mice”, 
based on the data obtained, doubling this cell dose will likely lead to better treatment of the 
aggressive GvHD that develops and may help to accentuate group differences. In summary, we 
have shown initial evidence that dual primed can significantly slow the progression of severe 
GvHD, whereas unprimed MSCs cannot.   
 
5.5 Future Directions 
We plan to continue performing xeno-GvHD mouse studies with larger sample sizes, as well as 
mid-point pathology, as the latter will permit the evaluation of disease progression by additional 
metrics such as tissue histology. From there, we may follow-up with a study in which MSCs are 
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administered 1-week into disease progression, which will test their ability to treat (not prevent) 
GvHD that has already developed.  
 While much progress has been made with our ex vivo tissue platform of GvHD, our initial 
focus will be to simply characterize and fully develop this as a disease model. Future students 
may test different therapeutics on this model or similar immune-competent engineered tissue 





















Decades of research have been devoted to understanding the biology and therapeutic potential of 
MSCs. This includes biochemical and animal studies, as well as hundreds of industry and 
academia-sponsored clinical trials. 
 The safety of using both autologous and allogenic MSCs is well-established, and the 
FDA has recently developed numerous strategies to facilitate the approval of novel cell and gene 
therapies, such as through the “regenerative medicine advanced therapy” (RMAT) designation 
that was provided by the 21st Century Cures Act. It appears that we are finally at the moment in 
history when regenerative medicine therapeutics could start to be FDA approved and reach 
patients in the United States. 
 Nevertheless, if MSCs continue to be tested in clinical trials without approaching their 
production differently, there is no reason to expect that the outcome should be any more 
favorable than it has been in previous clinical trials. Given the multipotent nature of these cells, 
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and their sensitivity to microenvironmental cues, injecting naïve, unprimed MSCs lends itself to 
wide variability in therapeutic activity, since the cells may adopt different behaviors based on 
each patients’ internal environment.  
 Our focus has been on developing MSCs as cell therapies to treat inflammatory 
conditions. To help create a uniform population of immunosuppressive cells, and reduce patient-
specific variability in MSC phenotype, our objective was to develop a brief in vitro priming 
regimen that the cells would undergo after they had been expanded to therapeutic cell numbers. 
We chose to perform an in-depth evaluation of two priming cues – hypoxia and IFN-γ - that had 
previously been cited to serve complementary purposes in the literature. Hypoxia was known to 
promote cell survival and IFN-γ was known to induce an immunosuppressive phenotype in 
MSCs. 
 In vitro studies uncovered that, indeed, both cues could instruct MSCs towards a more 
anti-inflammatory state. IFN-γ accomplished this via promoting the upregulation of immune-
regulatory proteins: HLA-G, HLA-E, IDO, PD-L1, and hypoxia accomplished this by altering 
MSC metabolism towards a glycolytic state that challenged T-cells in the environment, which 
are also dependent on glycolysis and sensitive to local lactate concentration. As these are distinct 
mechanisms of action, it was not surprising that dual priming MSCs with both cues led to twice 
the improvement in immunosuppressive capacity over either cue alone. 
 To more fully understand how priming with hypoxia, IFN-γ, and their combination 
affected MSC behavior, we followed up our in vitro immune suppression studies with a global 
proteomic and metabolic analysis. This revealed two distinct patterns of adaptations that MSCs 
make to each cue.  
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MSCs respond to IFN-γ in a manner that makes sense in the context of wound healing. 
The cells upregulate their anti-pathogen response to eliminate foreign invaders, upregulate 
several immunosuppressive proteins to prevent pathological inflammation, and increase their 
expression of factors that promote their own survival from immune mediated clearance. 
Additionally, cells decrease ECM deposition, which serves as an anti-fibrotic mechanism. The 
response to hypoxia serves an entirely different purpose, which is to engage pathways that permit 
cell survival in a low oxygen setting.  
Hypoxia primed MSCs switch to glycolysis for energy and down regulate oxygen-
dependent mechanisms of metabolism. They also increase proteins involved in autophagy and 
cell migration. As with our earlier studies, we found these changes were additive for dual primed 
MSCs, although there were many synergies, particularly when it came to ECM deposition and 
modification. These studies lent much insight (including some novel mechanisms) to our 
understanding of MSC biology, and they suggested how using IFN-γ and hypoxia together could 
confer many benefits to MSCs used clinically. 
 To evaluate the primed cells in the setting of disease, we turned to a xenogeneic mouse 
model of GvHD and started to develop an engineered tissue model of skin GvHD as a parallel 
testing platform. Our preliminary mouse model findings support that priming enables MSCs to 
better prevent GvHD, and we are optimistic about the confirmatory studies that are planned for 
the next several months. The hope is that the science of priming MSCs, which we have advanced 
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Target Clone Fluorophore Antibody Dilution Source 
CD3 UCHT1 PerCP-
Cy™5.5 
1:20  BD 
CD4 RPA-T4 PE-Cy7 1:80  BD 
CD8 SK1 APC-Cy7 1:40  BD 
CD107a H4A3  PE 1:5  BD 
CD25 M-A251 APC 1:5  BD 
CD45RA HI100 V500 1:20  BD 
CCR7 150503 FITC 1:20  BD 
HLA-G MEM-G/9 FITC 1:10 Abcam 
IDO eyedio eFluor660 1:20 eBioscience 
CD274 (PD-L1) MIH1 eFluor450 1:20 eBioscience 
COX-2 AS66 FITC 1:20 Cayman 
HLA-E 3D12 APC 1:10 Miltenyi 
GLUT1 SPM498 APC 1:500 Abcam 	
	 92	
Table S2 Forward and reverse primers for immunosuppressive genes  
 
Abbreviations: glyceraldehyde 3-phosphate dehydrogenase (GAPDH), human leukocyte antigen-G (HLA-G), 
human leukocyte antigen-E (HLA-E), hepatocyte growth factor (HGF), cyclo-oxgenase-2 (COX-2), inducible nitric 
oxide synthase (iNOS), indoleamine-2,3-dioxygenase (IDO), leukemia inhibitory factor (LIF), interleukin-10 (IL-
10), transforming growth factor- β (TGF- β), tumor necrosis factor-inducible gene 6 (TSG-6), programmed death 










 Forward Reverse 
GAPDH AAGGTGAAGGTCGGAGTCAAC GGGGTCATTGATGGCAACAATA 
HLA-G GAAGAGGAGACACGGAACA TGGCCTCATAGTCAAAGACA 
HLA-E ATGGAACCCTCCTTTTACTC GGCTCCAGGTGAAGCAGC 
HGF GGTGACCAAACTCCTGCCA ACCTCTGGATTGCTTGTGAAA 
COX2   CAGCCATACAGCAAATCC ATCCTGTCCGGGTACAAT  
iNOS TCATCCGCTATGCTGGCTAC CCCGAAACCACTCGTATTTGG 
IDO TCTCATTTCGTGATGGAGACTGC GTGTCCCGTTCTTGCATTTGC 
LIF CCAACGTGACGGACTTCCC TACACGACTATGCGGTACAGC 
IL-10 TCAAGGCGCATGTGAACTCC GATGTCAAACTCACTCATGGCT 
TGF-β GGCCAGATCCTGTCCAAGC GTGGGTTTCCACCATTAGCAC 
TSG-6 GGGCAGAGTTGGATACCCC TGCGTGTGGGTTGTAGCAATA 
CD59 TTTTGATGCGTGTCTCATTACCA ATTTTCCCTCAAGCGGGTTGT 
PD-L1 GGACAAGCAGTGACCATCAAG CCCAGAATTACCAAGTGAGTCCT 
Arginase-1 GTGGAAACTTGCATGGACAAC AATCCTGGCACATCGGGAATC 
Galectin-1 TCGCCAGCAACCTGAATCTC GCACGAAGCTCTTAGCGTCA 
Galectin-3 GTGAAGCCCAATGCAAACAGA AGCGTGGGTTAAAGTGGAAGG 
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Table S3 Mean fluorescence intensity ± SD of GLUT1 expression on CD4+ and CD8+ T-cell subsets 
in MSC-MLR co-culture studies on days 1 and 3.  
 
 
Note: There were ~4,000 events in the CD4 gate and ~1,000 events in CD8 gate for each sample; ANOVA analysis 
showed that GLUT1 expression in the MLR + D MSCs condition was significantly lower (****) than all other MLR 
conditions; on Day 1, there was not even a significant difference between Responder Only and MLR + D MSC 
 
 











 CD4+ CD8+ 
 Day 1 Day 3 Day 1 Day 3 
Responder Only 2711 ± 958 2796 ± 938 2792 ± 1416 2482 ± 828 
MLR 2792 ±1089 3792 ± 2360 2859 ± 1297 3649 ± 3000 
MLR + C MSCs  3886 ± 1782 4166 ± 2444 4044 ± 1921 4176 ± 2702 
MLR + I MSCs 3957 ± 1811 3809 ± 2352 4535 ± 2413 3895 ± 2664 
MLR + H MSCs 3408 ± 1519 3838 ± 2361 3638 ± 1838 3610 ± 2106 
MLR + D MSCs 2636 ± 1200 3170 ± 1728 2801 ± 1577 2884 ± 1889 	
 IDO HLA-G HLA-E COX-2 PD-L1 
C MSCs 299 ± 227 564 ± 570 2396 ± 3640 310 ± 2003 169 ± 288 
I MSCs 20 900 ± 11 087 668 ± 680 8848 ± 7296 337 ± 796 611 ± 489 
H MSCs 482 ± 2405 554 ±797 2375 ± 4580 358 ± 1222 167 ± 265 
D MSCS 31,766 ± 16,677 796 ± 1212 9721 ± 6944 336 ± 827 575 ± 435 	
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 Daily Glucose Consumption Daily Lactate Production 
 Day 1 Day 2-3 Avg Day 1 Day 2-3 Avg 
Responder Only 3.65 8.53 < 1 1.97 
MLR Only 6.80 15.38 < 1 2.92 
MLR + C MSCs 34.45 40.33 5.61 7.85 
MLR + I MSCs 46.10 40.45 6.88 7.36 
MLR + H MSCs 61.55 39.50 9.22 5.53 
MLR + D MSCs 70.85 45.60 14.08 6.30 	
[Lactate] Median Fluorescence Intensity (pHrodo Red) 
0 mM 4974 
5 mM 5891 
10 mM 6176 
15 mM 7503 
20 mM 8761 
30 mM 14108 	
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	Target Clone Fluorophore Concentration Source 
CD11c 3.9 APC 1:20 ebioscience 
CD14 M5E2  FITC 1:5  BD 
CD36 CB38 PE 1:5  BD 
CD80 L307.4 FITC 1:5  BD 
CD207 
(Langerin) 
2G3 PE 1:20 BD 
CD209  
(DC-SIGN) 
DCN46 FITC 1:5  BD 
CD324  
(E-cadherin) 
67A4  FITC 1:20 Biolegend 
HLA-DR G46-6 PE 1:20 BD 
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SUPPLEMENTAL FIGURES 	 												









Figure S2	The effect of hypoxia and/or IFN-γ priming on the average cell diameter. Cell diameter was 
determined immediately after passaging using a Countess device. n=5 experiments were averaged. All pairwise 




































































Figure S3 Confirming trends found via mass spectroscopy for select proteins. A) Flow cytometry was used to 
assess how IFN-γ and/or hypoxia affected expression of some proteins that had been detected by a single peptide via 
mass spectroscopy (CFH, HLA-F,PD-L1) or had shown a DE of small magnitude on mass spectroscopy (CD47, 
LRRC32, TGF-B1). B) Lysyl oxidase activity assay was used to confirm the increased activity/expression of this 
family of proteins upon exposure to hypoxia (or dual hypoxia/IFN-γ). C) ANGPTL4 ELISA was used to confirm the 
upregulation of this protein under hypoxia or dual hypoxia/IFN-γ priming. D) CFH Western Blot was a second 
means of confirming the upregulation by IFN-γ and dual priming seen from the mass spec data. * p<0.05, *** 
p<0.0001   
						 
































































































































































Figure S4 The effect of dual priming on the expression of proteins in the glucagon signaling pathway. The heat 
map at the top left shows the log2 fold change difference in expression of proteins, where blue indicates a down-
regulated protein and red indicates an upregulated protein. Only those proteins that met our criteria for differential 






Figure S5 The effect of IFN-γ priming on the expression of proteins in the antigen presentation cascade. The 
heat map at the top left shows the log2 fold change difference in expression of proteins, where blue indicates a 
down-regulated protein and red indicates an upregulated protein. Only those proteins that met our criteria for 
differential expression are shown (log2FC > 0.6 and p< 0.05) 
 
 
